Podcasts about hipa

Send us a textOn this week of Serious Privacy,  Ralph O'Brien of Reinbo Consulting, and Dr. K Royal connect to cover a week in privacy as Paul Breitbarth is away. This weeks shorter episode includes a guide to what's coming up from Serious Privacy at IAPP summit in DC, a penalty from the UK ICO, EDPB draft Guidance on blockchain, state laws, enforcement actions, and more!Please subscribe in your favorite podcast app - sharing is caring! Some resourceshttps://ico.org.uk/about-the-ico/media-centre/news-and-blogs/2025/04/law-firm-fined-60-000-following-cyber-attack/https://www.edpb.europa.eu/news/news/2025/edpb-adopts-guidelines-processing-personal-data-through-blockchains-and-ready_enhttps://iapp.org/resources/article/us-state-privacy-legislation-tracker/#state-privacy-law-chart Powered by TrustArcSeamlessly manage your privacy program, assess risks, and stay up to date on laws across the globe.With TrustArc's Privacy Studio and Governance Suite, you can automate cookie compliance, streamline data subject rights, and centralize your privacy tasks—all while reducing compliance costs. Visit TrustArc.com/serious-privacy.If you have comments or questions, find us on LinkedIn and Instagram @seriousprivacy, and on BlueSky under @seriousprivacy.eu, @europaulb.seriousprivacy.eu, @heartofprivacy.bsky.app and @igrobrien.seriousprivacy.eu, and email podcast@seriousprivacy.eu. Rate and Review us! From Season 6, our episodes are edited by Fey O'Brien. Our intro and exit music is Channel Intro 24 by Sascha Ende, licensed under CC BY 4.0. with the voiceover by Tim Foley.

TI: Láncziék törvénysértő jelentést készítettek 24.hu     2024-10-15 11:51:08     Belföld Korrupció Transparency International A Transparency International szerint a dokumentum tele van kitalációkkal, tárgyi tévedésekkel és súlyos csúsztatásokkal. Reagált a kormány arra, hogy az OECD korrupció elleni munkacsoportja lemondta budapesti misszióját Telex     2024-10-15 14:44:46     Gazdaság Korrupció OECD Az OECD munkacsoportja szerint nem tudták őket miniszteri szinten fogadni. A kormány azt ígéri: fogják. Nemet mondott Olaf Scholznak az albán miniszterelnök HírTV     2024-10-15 10:51:06     Külföld Németország Berlin Balkán Albánia OLAF Udvariasan elutasította Németország közeledését Edi Rama albán miniszterelnök a berlini Nyugat-Balkán Konferencián – jelenti a Euronews. Egyre biztosabb: külföldi katonák ezrei sietnek Oroszország segítségére, már azt is tudni, mennyien érkeznek Portfolio     2024-10-15 16:16:00     Külföld Ukrajna Moszkva Titkosszolgálat Észak-Korea Az orosz hadsereg súlyos létszámhiánnyal küzd az ukrajnai frontvonalakon, ebben Észak-Korea nagyszabású támogatással igyekszik Moszkva segítségére. Az ukrán katonai hírszerzés (GUR) forrásai szerint Phenjan nemcsak fegyvereket és felszerelést, hanem katonai személyzetet is biztosít Moszkvának - írta a Kyiv Post. Nyugdíjmegtakarítás lakásra: megjelent a tervezet, de sok a tisztázatlan kérdés 444.hu     2024-10-15 12:26:24     Gazdaság Nyugdíj Nyugdíjpénztár Törlesztés Jövőre akár háromszor is hozzányúlhatunk az önkéntes nyugdíjpénztárban lévő pénzünkhöz, és akár már idén októbertől gyűjthetjük a számlát. A csupán másfél oldalas törvénytervezet azonban sok nagyon fontos kérdésre nem ad választ. Mi lesz az építkezőkkel, csak az adófizetést ússzuk-e meg, mit jelent a törlesztés? Hipa-átalakítás: lehet, hogy a gazdag városoknak nem tetszik, de háromezer település a nyertese lesz vg.hu     2024-10-15 16:18:50     Belföld Önkormányzat A teljes hipa-bevétel közel kétharmada összesen 47 önkormányzattól származik, azaz az összes többi, 3145 önkormányzat osztozik az adónemből származó befizetés egyharmadán. 45 milliárdot loptak el tőlünk egy év alatt a kiberbűnözők Forbes     2024-10-15 12:18:07     Gazdaság Kibertámadás Az összeg egyre nagyobb része a kártya- és számabirtokost terheli. Mi történt? Egy-egy számla elleni támadásban a lakossági ügyfelektől közel 1,2 millió forintot loptak el a csalók. Az elmúlt egy év adatai alapján tehát összesen 45 milliárddal rövidítették meg a digitálisan fizetőket – hívja fel a figyelmet Gergely Péter, a BiztosDöntés.hu pénzügyi Nem magyar utakra való az új magyar autó Vezess     2024-10-15 15:03:30     Autó-motor Győr Többszöri találkozás után végre vezethettük is a Cupra Terramart. Büszkék lehetnek rá a győriek, bár a magyarok kevésbé tudják élvezni, amit nyújtani képes. Pokolgépes merénylet történt Moszkvában Magyar Hírlap     2024-10-15 17:32:43     Külföld Terrortámadás Moszkva A hatóságok szerint a vezetőülés felőli oldalra a motorháztető alá szerelt házi készítésű robbanószerkezet kis erősségű volt. RTL Leaks – Interjú Dirk Gerkens, az RTL Magyarország leváltott vezérigazgatójának ügyvédjével egy titokban készült hangfelvételről, ami szerint a magyar kormány nyomására távolították el Gerkenst Media1     2024-10-15 15:09:32     Média Párkapcsolat Interjú Hangfelvétel RTL Klub Dirk Gerkens Egy, a Media1 birtokában lévő, közel 50 perces hangfelvételen Guillaume de Posch, az RTL Group társ-vezérigazgatója olyan kijelentéseket tett 2015-ben Dirk Gerkensnek, az RTL Magyarország vezérigazgatójának egy másik RTL-es vezető társaságában, hogy Gerkenst a magyar kormány nyomásgyakorlása miatt távolítják el a médiavállalat éléről. A Media1 az ü Máris győzelmet aratott Orbán Viktor az uniós határokon? Privátbankár     2024-10-15 11:58:00     Külföld Orbán Viktor Az uniós elnökség egyik fontos témájával kapcsolatban igen szép számokat hozott egy friss jelentés. Halálos rollerbaleset: elhunyt Jenei István Sportal     2024-10-15 13:34:09     Sport Negyvennyolc éves korában elhunyt Jenei István, világbajnok és háromszoros Superbody bronzérmes testépítő, mesteredző, akinek keze alá számos magyar testépítő tartozott - számolt be róla a shopbuilder.hu. Megérdemelt győzelem Boszniában, szinte elképzelhetetlen az egyenes ági kiesés Büntető.com     2024-10-15 14:03:10     Foci Németország Magyar foci Hollandia Bosznia-Hercegovina A magyar labdarúgó-válogatott azzal a tudattal lépett pályára Bosznia-Hercegovinában, hogy bármennyire is előzékeny vendég, nem engedheti maga elé a táblázaton az addig egypontos házigazdát. Nekünk a döntetlen is kedvezett volna, ismerve, hogy a hátralévő novemberi meccseken Hollandia és Németország lesz az ellenfele mindkét csapatnak, ám Szoboszl Így ment el az év üstököse a Nap mellett Kiderül     2024-10-15 18:06:46     Időjárás Világűr A SOHO űrszonda megörökítette, ahogy az év üstököse a múlt héten elhalad a Nap mellett. A videón azonban más érdekesség is megfigyelhető. A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

TI: Láncziék törvénysértő jelentést készítettek 24.hu     2024-10-15 11:51:08     Belföld Korrupció Transparency International A Transparency International szerint a dokumentum tele van kitalációkkal, tárgyi tévedésekkel és súlyos csúsztatásokkal. Reagált a kormány arra, hogy az OECD korrupció elleni munkacsoportja lemondta budapesti misszióját Telex     2024-10-15 14:44:46     Gazdaság Korrupció OECD Az OECD munkacsoportja szerint nem tudták őket miniszteri szinten fogadni. A kormány azt ígéri: fogják. Nemet mondott Olaf Scholznak az albán miniszterelnök HírTV     2024-10-15 10:51:06     Külföld Németország Berlin Balkán Albánia OLAF Udvariasan elutasította Németország közeledését Edi Rama albán miniszterelnök a berlini Nyugat-Balkán Konferencián – jelenti a Euronews. Egyre biztosabb: külföldi katonák ezrei sietnek Oroszország segítségére, már azt is tudni, mennyien érkeznek Portfolio     2024-10-15 16:16:00     Külföld Ukrajna Moszkva Titkosszolgálat Észak-Korea Az orosz hadsereg súlyos létszámhiánnyal küzd az ukrajnai frontvonalakon, ebben Észak-Korea nagyszabású támogatással igyekszik Moszkva segítségére. Az ukrán katonai hírszerzés (GUR) forrásai szerint Phenjan nemcsak fegyvereket és felszerelést, hanem katonai személyzetet is biztosít Moszkvának - írta a Kyiv Post. Nyugdíjmegtakarítás lakásra: megjelent a tervezet, de sok a tisztázatlan kérdés 444.hu     2024-10-15 12:26:24     Gazdaság Nyugdíj Nyugdíjpénztár Törlesztés Jövőre akár háromszor is hozzányúlhatunk az önkéntes nyugdíjpénztárban lévő pénzünkhöz, és akár már idén októbertől gyűjthetjük a számlát. A csupán másfél oldalas törvénytervezet azonban sok nagyon fontos kérdésre nem ad választ. Mi lesz az építkezőkkel, csak az adófizetést ússzuk-e meg, mit jelent a törlesztés? Hipa-átalakítás: lehet, hogy a gazdag városoknak nem tetszik, de háromezer település a nyertese lesz vg.hu     2024-10-15 16:18:50     Belföld Önkormányzat A teljes hipa-bevétel közel kétharmada összesen 47 önkormányzattól származik, azaz az összes többi, 3145 önkormányzat osztozik az adónemből származó befizetés egyharmadán. 45 milliárdot loptak el tőlünk egy év alatt a kiberbűnözők Forbes     2024-10-15 12:18:07     Gazdaság Kibertámadás Az összeg egyre nagyobb része a kártya- és számabirtokost terheli. Mi történt? Egy-egy számla elleni támadásban a lakossági ügyfelektől közel 1,2 millió forintot loptak el a csalók. Az elmúlt egy év adatai alapján tehát összesen 45 milliárddal rövidítették meg a digitálisan fizetőket – hívja fel a figyelmet Gergely Péter, a BiztosDöntés.hu pénzügyi Nem magyar utakra való az új magyar autó Vezess     2024-10-15 15:03:30     Autó-motor Győr Többszöri találkozás után végre vezethettük is a Cupra Terramart. Büszkék lehetnek rá a győriek, bár a magyarok kevésbé tudják élvezni, amit nyújtani képes. Pokolgépes merénylet történt Moszkvában Magyar Hírlap     2024-10-15 17:32:43     Külföld Terrortámadás Moszkva A hatóságok szerint a vezetőülés felőli oldalra a motorháztető alá szerelt házi készítésű robbanószerkezet kis erősségű volt. RTL Leaks – Interjú Dirk Gerkens, az RTL Magyarország leváltott vezérigazgatójának ügyvédjével egy titokban készült hangfelvételről, ami szerint a magyar kormány nyomására távolították el Gerkenst Media1     2024-10-15 15:09:32     Média Párkapcsolat Interjú Hangfelvétel RTL Klub Dirk Gerkens Egy, a Media1 birtokában lévő, közel 50 perces hangfelvételen Guillaume de Posch, az RTL Group társ-vezérigazgatója olyan kijelentéseket tett 2015-ben Dirk Gerkensnek, az RTL Magyarország vezérigazgatójának egy másik RTL-es vezető társaságában, hogy Gerkenst a magyar kormány nyomásgyakorlása miatt távolítják el a médiavállalat éléről. A Media1 az ü Máris győzelmet aratott Orbán Viktor az uniós határokon? Privátbankár     2024-10-15 11:58:00     Külföld Orbán Viktor Az uniós elnökség egyik fontos témájával kapcsolatban igen szép számokat hozott egy friss jelentés. Halálos rollerbaleset: elhunyt Jenei István Sportal     2024-10-15 13:34:09     Sport Negyvennyolc éves korában elhunyt Jenei István, világbajnok és háromszoros Superbody bronzérmes testépítő, mesteredző, akinek keze alá számos magyar testépítő tartozott - számolt be róla a shopbuilder.hu. Megérdemelt győzelem Boszniában, szinte elképzelhetetlen az egyenes ági kiesés Büntető.com     2024-10-15 14:03:10     Foci Németország Magyar foci Hollandia Bosznia-Hercegovina A magyar labdarúgó-válogatott azzal a tudattal lépett pályára Bosznia-Hercegovinában, hogy bármennyire is előzékeny vendég, nem engedheti maga elé a táblázaton az addig egypontos házigazdát. Nekünk a döntetlen is kedvezett volna, ismerve, hogy a hátralévő novemberi meccseken Hollandia és Németország lesz az ellenfele mindkét csapatnak, ám Szoboszl Így ment el az év üstököse a Nap mellett Kiderül     2024-10-15 18:06:46     Időjárás Világűr A SOHO űrszonda megörökítette, ahogy az év üstököse a múlt héten elhalad a Nap mellett. A videón azonban más érdekesség is megfigyelhető. A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

We dissect Producer Josh's seventh inning stretch from yesterday at the Storm Chasers game, Connor's trip to the supermarket, Matt Rhule's HIPA violation, the Nebraska-Creighton Volleyball rivalry, Gary asks about the Gretna outlet malls, Nebraska's opening night announcement, and an AL MVP debate, and we ask if anyone knows who Derrick White is.

Csak az nem talál orosz propagandát a kormánypárti sajtóban, aki nem keresi Telex     2024-07-10 12:04:35     Belföld Ukrajna háború Propaganda A kormánypárti sajtóban naponta jelennek meg hírek, cikkek az ukrajnai háborút övező orosz álláspontokról, de a Szuverenitásvédelmi Hatóság valahogy mégsem vette ezt észre, amikor médiumokat listázott. Sikertörténet a középiskolások katonai képzése 24.hu     2024-07-10 15:56:27     Belföld Középiskola A KDNP frakcióvezetője úgy gondolja, a fiatalok szabadidős tevékenységet látnak a búvárkodásban, de mindig is volt katonai jelentősége. Von der Leyent eszi a méreg HírTV     2024-07-10 11:12:06     Külföld Orbán Viktor Európai Bizottság Ursula von der Leyen Ursula von der Leyen, az Európai Bizottság elnöke "rendkívül elégedetlen" Orbán Viktor békemissziójával – idézi a RIA Florian Philippot-t, a francia Hazafiak párt vezetőjét. Csalás nélkül is borulhat a fővárosi eredmény, de Karácsony Gergely és Vitézy Dávid sem fog nyerni Privátbankár     2024-07-10 13:54:03     Gazdaság Karácsony Gergely Vitézy Dávid Nem kell megijedni attól, hogy találnak elszámolt főpolgármester-jelölti szavazatokat. De ha ebből valaha is jogerős eredmény lesz, az már sem Karácsony Gergelyen, sem Vitézy Dávidon nem fog segíteni. Nyugati alkatrészekkel lőttek az oroszok a kijevi gyerekkórházra 444.hu     2024-07-10 15:01:43     Külföld Ukrajna USA Kijev Kínán keresztül szerzik be az amerikai chipeket, amiket aztán a KH-101 cirkálórakétába építenek. Egy ilyen találta el hétfőn az Ohmatgyit gyermekklinikát. Már most látszik, miként nyerhetnek a NER milliárdosai a repteren Azenpenzem     2024-07-10 15:33:00     Gazdaság Nemzetgazdaság NER Koncesszió Még vizsgálják, miből fejlesztik majd a repteret – derült az NGM vezetője tájékoztatásából. Azt viszont már tudatták, hogy koncessziós üzemeltetés is elképzelhető. Erről pedig az eddigi tapasztalatok alapján lehetnek elképzeléseink. Tisztázta a kormány, lesz-e Pécs környékén akkumulátorgyár vg.hu     2024-07-10 11:03:17     Belföld Baranya Pécs Környezetvédelem A HIPA vezetője szerint ma Magyarországon egyetlen olyan üzem sem épülhet meg vagy működhet, amely nem tartja be a rendkívül szigorú környezetvédelmi előírásokat. Incidens történt a Barents-tengeren: Poseidont fogott el az orosz légierő Portfolio     2024-07-10 15:42:00     Külföld Repülőtér Repülőgép Elfogott egy P-8A Poseidon típusú felderítő repülőgépet az orosz légierő a Barents-tengeren – írja a Sky News és több orosz forrás. Amerikát idegesíti, de nagyon jó üzletnek bizonyul a Raiffeisen bank oroszországi tevékenysége Forbes     2024-07-10 14:00:08     Cégvilág USA Raiffeisen Az amerikaiak nagyon súlyos fenyegetése kellett ahhoz, hogy kihátráljanak egy üzletből. De így is nagyon jól kerestek az orosz piacon. Zelenszkij: "nem tudom, mi lesz, ha ismét Trump lesz az elnök" Liner     2024-07-10 10:43:41     Külföld Ukrajna NATO Volodimir Zelenszkij Donald Trump Az ukrán elnök kijelentései különösen fontosak most, amikor a világ vezetői éppen a NATO e heti csúcstalálkozójára gyűlnek össze. Múosz: „Békemisszióban háború indult a független sajtó ellen” Media1     2024-07-10 11:34:38     Média háború Propaganda MÚOSZ Állásfoglalást adott ki a MÚOSZ (Magyar Újságírók Országos Szövetsége), melyben elítél minden olyan hatalmi akciót, mellyel a független sajtó működését kívánják akadályozni. E törekvések közé sorolják azt a hétfőn villámgyorsan megjelent kormányhatározatot, mely elvben a háborús propaganda ellen szól, valójában azonban újra a független média normál Podolski kebabban utazik, Saha "üzleti Tinderben", Owen lovakban Büntető.com     2024-07-10 13:06:31     Foci Ghána Asamoah Gyan Különleges lista jön össze azokból a civil befektetésekből, amelyeket volt klasszis labdarúgók jegyeznek. A világbajnok Lukas Podolski a kebabra és jégkrémre esküszik, a ghánai Asamoah Gyan légitársaságot, Michael Owen lóversenyistállót alapított. Hengereltek a magyarok: világverő csapatot győzött le válogatottunk Magyar Nemzet     2024-07-10 10:41:34     Sport USA Vízilabda A női vízilabda-válogatott az Egyesült Államokban, amerikai bírók mellett nyert a hazai csapat ellen. Megvan a hét első melegrekordja Kiderül     2024-07-10 15:06:12     Időjárás Július 9-én 38,1 fokkal megdőlt az aznapra vonatkozó maximumhőmérséklet rekordja. A hét végéig valószínűleg nem ez volt az utolsó ilyen alkalom. A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

Csak az nem talál orosz propagandát a kormánypárti sajtóban, aki nem keresi Telex     2024-07-10 12:04:35     Belföld Ukrajna háború Propaganda A kormánypárti sajtóban naponta jelennek meg hírek, cikkek az ukrajnai háborút övező orosz álláspontokról, de a Szuverenitásvédelmi Hatóság valahogy mégsem vette ezt észre, amikor médiumokat listázott. Sikertörténet a középiskolások katonai képzése 24.hu     2024-07-10 15:56:27     Belföld Középiskola A KDNP frakcióvezetője úgy gondolja, a fiatalok szabadidős tevékenységet látnak a búvárkodásban, de mindig is volt katonai jelentősége. Von der Leyent eszi a méreg HírTV     2024-07-10 11:12:06     Külföld Orbán Viktor Európai Bizottság Ursula von der Leyen Ursula von der Leyen, az Európai Bizottság elnöke "rendkívül elégedetlen" Orbán Viktor békemissziójával – idézi a RIA Florian Philippot-t, a francia Hazafiak párt vezetőjét. Csalás nélkül is borulhat a fővárosi eredmény, de Karácsony Gergely és Vitézy Dávid sem fog nyerni Privátbankár     2024-07-10 13:54:03     Gazdaság Karácsony Gergely Vitézy Dávid Nem kell megijedni attól, hogy találnak elszámolt főpolgármester-jelölti szavazatokat. De ha ebből valaha is jogerős eredmény lesz, az már sem Karácsony Gergelyen, sem Vitézy Dávidon nem fog segíteni. Nyugati alkatrészekkel lőttek az oroszok a kijevi gyerekkórházra 444.hu     2024-07-10 15:01:43     Külföld Ukrajna USA Kijev Kínán keresztül szerzik be az amerikai chipeket, amiket aztán a KH-101 cirkálórakétába építenek. Egy ilyen találta el hétfőn az Ohmatgyit gyermekklinikát. Már most látszik, miként nyerhetnek a NER milliárdosai a repteren Azenpenzem     2024-07-10 15:33:00     Gazdaság Nemzetgazdaság NER Koncesszió Még vizsgálják, miből fejlesztik majd a repteret – derült az NGM vezetője tájékoztatásából. Azt viszont már tudatták, hogy koncessziós üzemeltetés is elképzelhető. Erről pedig az eddigi tapasztalatok alapján lehetnek elképzeléseink. Tisztázta a kormány, lesz-e Pécs környékén akkumulátorgyár vg.hu     2024-07-10 11:03:17     Belföld Baranya Pécs Környezetvédelem A HIPA vezetője szerint ma Magyarországon egyetlen olyan üzem sem épülhet meg vagy működhet, amely nem tartja be a rendkívül szigorú környezetvédelmi előírásokat. Incidens történt a Barents-tengeren: Poseidont fogott el az orosz légierő Portfolio     2024-07-10 15:42:00     Külföld Repülőtér Repülőgép Elfogott egy P-8A Poseidon típusú felderítő repülőgépet az orosz légierő a Barents-tengeren – írja a Sky News és több orosz forrás. Amerikát idegesíti, de nagyon jó üzletnek bizonyul a Raiffeisen bank oroszországi tevékenysége Forbes     2024-07-10 14:00:08     Cégvilág USA Raiffeisen Az amerikaiak nagyon súlyos fenyegetése kellett ahhoz, hogy kihátráljanak egy üzletből. De így is nagyon jól kerestek az orosz piacon. Zelenszkij: "nem tudom, mi lesz, ha ismét Trump lesz az elnök" Liner     2024-07-10 10:43:41     Külföld Ukrajna NATO Volodimir Zelenszkij Donald Trump Az ukrán elnök kijelentései különösen fontosak most, amikor a világ vezetői éppen a NATO e heti csúcstalálkozójára gyűlnek össze. Múosz: „Békemisszióban háború indult a független sajtó ellen” Media1     2024-07-10 11:34:38     Média háború Propaganda MÚOSZ Állásfoglalást adott ki a MÚOSZ (Magyar Újságírók Országos Szövetsége), melyben elítél minden olyan hatalmi akciót, mellyel a független sajtó működését kívánják akadályozni. E törekvések közé sorolják azt a hétfőn villámgyorsan megjelent kormányhatározatot, mely elvben a háborús propaganda ellen szól, valójában azonban újra a független média normál Podolski kebabban utazik, Saha "üzleti Tinderben", Owen lovakban Büntető.com     2024-07-10 13:06:31     Foci Ghána Asamoah Gyan Különleges lista jön össze azokból a civil befektetésekből, amelyeket volt klasszis labdarúgók jegyeznek. A világbajnok Lukas Podolski a kebabra és jégkrémre esküszik, a ghánai Asamoah Gyan légitársaságot, Michael Owen lóversenyistállót alapított. Hengereltek a magyarok: világverő csapatot győzött le válogatottunk Magyar Nemzet     2024-07-10 10:41:34     Sport USA Vízilabda A női vízilabda-válogatott az Egyesült Államokban, amerikai bírók mellett nyert a hazai csapat ellen. Megvan a hét első melegrekordja Kiderül     2024-07-10 15:06:12     Időjárás Július 9-én 38,1 fokkal megdőlt az aznapra vonatkozó maximumhőmérséklet rekordja. A hét végéig valószínűleg nem ez volt az utolsó ilyen alkalom. A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

*Check out EZ's morning radio show "The InZane Asylum Q100 Michigan with Eric Zane" Click here*Support the show and enjoy great products! Check out EZ on Vouch!*Get a FREE 7 day trial to Patreon to "try it out."*Watch the show live, daily at 8AM EST on Twitch! Please click here to follow the page.Email the show on the Shoreliners Striping inbox: eric@ericzaneshow.comTopics:*So EZ finally got some news from the doc about the state of affairs with his balls. A full, HIPA-approved breakdown commences.*Jeffery Ross somehow avoided any #MeToo backlash, despite claims he dated a 15 year-old girl.*The latest Hollywood pervert is revealed.*Kyle from a company that used to market on the EZSP.*Muff Tat Dog Bitch avoids jailtime somehow.*Giesele Bundchen has meltdown on police body cam over paparazzi.*Rap concert shows balcony swaying with beat.*Asshole of the Day BTYB TC PaintballSponsors:Berlin Raceway, Impact Powersports, Frank Fuss / My Policy Shop Insurance, Kings Room Barbershop, A&E Heating and Cooling, The Mario Flores Lakeshore Team of VanDyk Mortgage, Shoreliners Striping, Ervines Auto Repair Grand Rapids Hybrid & EV, TC PaintballInterested in advertising? Email eric@ericzaneshow.com and let me design a marketing plan for you.Contact: Shoreliners Striping inbox eric@ericzaneshow.comDiscord LinkEZSP TikTokSubscribe to my YouTube channelHire me on Cameo!Tshirts available herePlease subscribe, rate & write a review on Apple Podcastspatreon.com/ericzaneInstagram: ericzaneshowTwitterOur Sponsors:* Check out eufy: us.eufy.comSupport this podcast at — https://redcircle.com/the-eric-zane-show-podcast/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Новости на радио «Русские Эмираты» в Дубае: - Brand Dubai, креативное подразделение медиа-офиса правительства Дубая, объявило о запуске конкурса на самые красивые фотографию и видеоролик об эмирате Хатта, который проводится совместно с Международной фотографической премией Хамдана (HIPA). - По итогам 2023 года население Дубая выросло на 100 тысяч человек, сообщили в Дубайском статистическом центре. Эмират стал магнитом для миллиардеров и миллионеров, а также ценных кадров и инвесторов, которые за последние два года создали множество новых рабочих мест.

Remember when music videos were on cable tv? We don't either! Join us in this podcast where we watch music videos that we haven't seen before and talk ALL about them! Get our reactions and our thoughts and find out if we will stream these songs in the future! Got a video for us to react to? Send it to us on our instagram page @videovirginspod ! This week we are coming to you LIVE from - The Local Mall Bathroom Alley FOLLOW us @johnbeforedawn and @joeistherealest  !!! Follow our special guest @ LAVQUIN and go to feat. Video Virgins | lavquin.com to find ALL of our links THERE! This episode's music videos are: 2000's Baby by BLP Kosher, One Margarita by That Chick Angel ft. Saucy Santana, Toxic by Lit Queen, Beautiful (2022 Version) by Christina Aguilera, She Gon Go by Trill Ryan ft. DMB Gotti, A Public Affair by Jessica Simpson, Black & White by Tom MacDonald, Adam Calhoun & Dax. First BLP Kosher's hair looks like a soufflé. Then That Chick Angel has a REALLY low tolerance. Then these girls in this Lit Queen video are getting tired. Then why is Christina Aguilera bringing this back? Then would we sleep with this yellow jacket? Then Ryan Seacrest is made of Hydro packets now. Then Tom MacDonald probably has an average dick? Dont forget to Like and leave a review!  Subscribe to our YOUTUBE - VIDEO VIRGINS and follow our Instagram @VIDEOVIRGINSPOD and our personal instagrams @JOEISTHEREALEST and @JOHNBEFOREDAWN BLP Kosher - 2000's Baby (Official Video) - YouTube One Margarita (Saucy Remix) [feat. Saucy Santana] - That Chick Angel, CasaDi, & Steve Terrell - YouTube Lit Queen "TOXIC" Prod. by @Rowezart - YouTube She Gon Go - Trill Ryan feat. DMB Gotti (Official Video) - YouTube Jessica Simpson - A Public Affair (Video) - YouTube Tom MacDonald, Adam Calhoun & Dax - Black & White - YouTube

How is clinical research becoming more patient-focused and more convenient for patients to participate in clinical trials? Why is a decentralized approach especially important concerning rare diseases? And how will digital innovation advance the way clinical research is conducted? We will learn those answers and more in this episode with Scott Schliebner, an innovative life sciences executive with 30 years of experience across the biopharma, CRO, medtech, and non-profit sectors. With a strategic and consultative approach to building and growing life science businesses, Scott has developed relationships, partnerships and collaborations that have driven commercial success. His vast experience includes leveraging real-world data and real-world evidence (RWE/RWD), leading technological innovation, and driving patient-focused paradigms to accelerate clinical drug development. Scott is an active board member, advisor, and mentor and his passions lie with infusing data and innovation into life sciences organizations—especially where rare diseases are concerned. He is currently the leading executive at Rare Clinical. -------------------------------------------------------- Episode Transcript: 00;00;00;07 - 00;00;24;21  How is clinical research becoming more patient focused and more convenient for patients to participate in? Why is a decentralized approach especially important when researching rare diseases? And what is the most likely future for how clinical research is conducted? We'll get the answers to all that and more on Research in Action.     00;00;24;23 - 00;00;48;24  Hello and welcome back to Research in Action, brought to you by Oracle. I'm Mike Stiles and our guest today is Scott Schliebner. Scott is a leader and innovative life sciences executive with 30 years experience across biopharma, CROs, medtech, and nonprofit. He's developed relationships, partnerships and collaborations that have driven commercial success with a strategic and consultative approach to building and growing life science businesses.     00;00;48;27 - 00;01;16;06  Scott got a lot of experience, including leveraging real-world data and real-world evidence, leading technological innovation and driving patient focused paradigms to accelerate clinical drug development. And he's an active board member, advisor and mentor, and he's all about infusing data and innovation into life sciences organizations, especially where rare disease is are concerned. And last but certainly not least, Scott is the leading executive at Rare Clinical.     00;01;16;09 - 00;01;35;01  Scott, we're glad to have you with us. Thanks for letting me grill you with all these questions. Thank you, Mike. My pleasure to be here with you. Well, let's start at the beginning. A fine place to start. What got you into the field of clinical research and drug discovery and why this special focus on rare diseases? Yeah, great.     00;01;35;01 - 00;02;04;13  It's a great place to start. I think, like a lot of my colleagues in this clinical research, clinical drug development profession, a lot of us sort of find our way into this field as there aren't necessarily a lot of like formal training programs or pathways necessarily. So for me, I was in graduate school, I was doing some more like I would call more basic science, more basic research that I found my one day struggling to.     00;02;04;16 - 00;02;22;00  As I was writing a grant for a professor, I found myself struggling to justify why, why this was really important. I kept saying to myself, Yeah, this doesn't really seem very applied. Is this really make a big difference? I, I can't convince myself this is critical. How am I going to convince a funder of our grant that this is really important?     00;02;22;00 - 00;02;44;17  And it kind of was a little bit of a light bulb moment for me that made me realize while I loved the field of research, I needed to be doing something that was more applied and could have a little bit more of a direct impact upon people. So it sort of led me to the clinical drug development space and clinical trials, and I got started back.     00;02;44;17 - 00;03;12;21  It's been a couple of decades now as I've been around for a little while, but it got started in a sort of like a biotech clinical research setting, helping to design and manage clinical trials and have been sort of engaged and passionate about this industry ever said. So it's been it's been a fun ride. But again, like a lot of people in this space, I think I stumbled into clinical research, maybe not accidentally, but, but, but there's not an obvious clear entry point for some of us.     00;03;12;23 - 00;03;33;25  Yeah. So I get that you, you got into the bio research space and drug development and those kind of things develop that interest. And I get that you wanted to make a real impact that you could feel like you were making a difference. Is that where the focus on rare diseases came into play or when did that? Yeah, thanks for following up on that part of the question.     00;03;33;25 - 00;04;12;02  I think that, yeah, after having been in the industry for a little while, you know, about, I don't know, this was probably like 12 years ago or something. Rare diseases at that time were really still a little bit. They weren't certainly a hot and sexy topic like they are today in 2023. But I came across some patients, I came across some patient groups, and I also came across a couple of clinical trials and I realized that what we were trying to do and what was required really to function and develop drugs in the space of rare diseases really required, honestly, a completely different, really way of operating a completely different paradigm than what we     00;04;12;02 - 00;04;48;16  were doing in most of clinical drug development. And with, you know, with our biopharma industry being pretty risk averse. That's a theme I think you'll hear come up probably a lot today. In our conversation. There hadn't been a lot of appetite or initiative around trying different approaches or looking at things differently. And these rare disease studies for sort of a countless sort of logistical and medical and scientific reasons really require a very different approach of, you know, you're talking about small populations that are geographically dispersed.     00;04;48;16 - 00;05;23;21  You're talking about patients that may have they may have to go through a diagnostic odyssey. A lot of people don't know about these disease states. There's a host of challenges that kind of come together and create a scenario that is even more complicated than your average challenging clinical trial. So also, when you look at the fact that there's something like 10,000 individual rare diseases individually, they're all rare little sub populations, but taken together they make up about 10% of the U.S. population and about 10% of the global population.     00;05;23;21 - 00;05;50;24  So it's it's a big area of unmet medical need. When you look at it from a big picture perspective, when you drill down into individual disease states, individual patient populations, you notice that these patients and families don't have any therapies, they don't have any treatments, they don't have a lot of hope sometimes. And clinical trials. And this world is really their only source of hope at times.     00;05;50;24 - 00;06;10;22  It's less of an experiment and more of a care or treatment option for rare disease patients. And so I found myself really immersed and passionate about this area and felt like it was a space that really needed new approaches. And I've been happy to kind of delve into that and try to make a difference there. And what is the state of that research like?     00;06;10;24 - 00;06;39;24  Is there reason for people with rare diseases to have hope? For instance, there are people in my family who have ankylosing spondylitis, which is a relatively rare form of arthritis. Is it appropriate for them to have hope that in their lifetime something's going to happen? Or are these populations so small and the research to develop drugs for it's so difficult that, you know, we're looking at 50, 60 years in the future before we make any progress.     00;06;39;25 - 00;06;55;20   Yeah, it's a great question. I mean, there really is a really broad spectrum here when we talk about rare diseases. We have such a such a large number of them. I think that the short answer is there is hope. And in a lot of cases that hope is in front of us or is on the very near horizon.     00;06;55;22 - 00;07;18;09  There certainly are other scenarios where another disease states where it's going to take a while and that hope is a little further out to be seen. But the good news is that we've well, there's been a lot of mobilization, there's been a lot of innovation and a lot of attention devoted to rare diseases over the last decade, 15 years, we've seen a lot of drug approvals.     00;07;18;11 - 00;07;39;24  We've seen a lot of companies, we've seen a lot of investment in biopharma biotech firms come into the rare disease space, whether they are small little biotech startups or whether they're the big pharma of the world. Everyone sees this as an opportunity to help develop drugs and help people. And in an area that really needs as much help as we can provide.     00;07;39;24 - 00;08;15;29  So there's a lot of hope. Some of these disease states are a little more clear than others. We understand the biology and the genetics, and maybe we can develop targeted therapies that help these patients some of these other more obscure, ultra rare or nano rare diseases. We're still learning who the patients are and how do we diagnose them and before we can develop a drug and show that it works and that it's safe in those populations, we need to first even understand a little bit about the natural history of some of these diseases and how they progressed kind of on their own and what kind of end points we would want to choose and some     00;08;15;29 - 00;08;37;27  things like that. But the bottom line is that there's a lot of hope, there's a lot of progress, there's a lot of activity, there's a lot of investment. I think there's a fair amount of awareness. We've seen a lot of progress here with people, with people and organizations and industry really getting into the space. Of course. With that said, there's a lot more that we can be doing.     00;08;37;27 - 00;09;02;21  There are a lot of disease states that really need some more attention and more funding and more research. But from where I sit, we've made some great strides and I hope to kind of keep accelerating that progress. Well, science is kind of inherently a social enterprise, but despite that, scientists and clinicians seem to work mostly behind closed doors, maybe even a little too far removed from the people they're actually working to help.     00;09;02;23 - 00;09;24;27  The pandemic changed a lot of things, but for one thing, Big pharma got kind of pushed out of its risk averse comfort zone because they had to speed the science and adopt more openness. So what do you think COVID did to innovation in the clinical research space? What changes are permanent and which ones aren't? Yeah, this is a fantastic topic.     00;09;24;27 - 00;09;57;11  We could we could spend a lot of time on those, I think. Well, necessity being the mother of invention, I think that COVID presented a lot of unique challenges and picking on my risk averse colleagues who may not want to necessarily try something new or go out on a limb with some sort of more risky, unproven approach. COVID forced us to reconsider how we were doing things, and it forced us to keep clinical trials going in a in a manner and keep them operating.     00;09;57;11 - 00;10;32;15    When we couldn't go to clinics or go to hospitals or when we had to social distance. And it forced us to really rethink a paradigm that had not really changed in many decades. So if you rewind a little bit to pre-COVID, there was several movements out there around creating more patient focused approaches. So this idea that you mentioned science being inherently a social enterprise, I envision a lot of clinical protocols and clinical trials being they're often developed in a little bit of a bubble.     00;10;32;18 - 00;11;01;01  Sometimes I'll joke and say in a conference room in New Jersey, right, these clinical trials come to life and are sketched out and designed in a little bit of an insulated bubble of sorts that don't really take into account the perspective and the input and the needs and the voice of the end users, namely the patients themselves. So similarly to the fact that, you know, you may have an iPhone sitting there on your desk next to you.     00;11;01;04 - 00;11;26;27  Apple, of course, didn't design a camera to put on their phone and say, let's see if people want to use a camera. The camera was designed, of course, by consumer demand and designed for the people using it. Ironically, even though science and even though clinical drug development is completely dependent upon patients participating in clinical trials, we rely on them and their data to move things forward.     00;11;26;29 - 00;12;06;22  They're very rarely considered actually, in the design process. Right. That's the irony, is that we rely on them. We must have their participation, but they're kind of an afterthought historically when it comes to designing a clinical trial and thinking about how to implement it. So that being sort of the baseline of how we've operated COVID hits and all of a sudden our world is interrupted and some of these novel approaches that had been being developed, these mobile health platforms, early COVID, we were talking about how can we make clinical trials, quote unquote virtual or hybrid with some of the language we were using.     00;12;06;24 - 00;12;35;18  How do we instead of requiring patients to maybe travel long distances to a clinical site or an academic medical center? Sometimes it could be a weekly visit for 52 weeks. A lot of times that's not going down to your neighborhood primary care physician. It might be driving into Manhattan and going to Memorial Sloan-Kettering every Friday afternoon and taking time off of work and away from your family and your children to participate in the clinical trial.     00;12;35;21 - 00;13;02;09  The bottom line, clinical trials were really not designed for patients, often not realistic and often not feasible. So when we ran into COVID and the challenges that kind of shutting down hospitals sort of created, it forced us to adopt this what we ended up naming decentralized clinical trial paradigm, and it forced us to think through, well, how do we bring clinical trials to patients themselves?     00;13;02;11 - 00;13;25;15  So this was a long, long overdue need that was out there. Again, we've been operating in a little bit of an archaic fashion for quite a while, putting out studies that were not realistic for patients. But when the world around us sort of crashed down and we needed a new approach, we adopted this more patient focused paradigm simply out of need, I think.     00;13;25;18 - 00;14;05;21  So there's been some traction with this. Decentralized clinical trials have become a common term in this industry. We have the Decentralized Trials and Research Alliance that was formed in 2020. There's a lot of companies on investment that have come up to develop this new paradigm of, instead of these critical end users, patients, instead of having them have to travel long distances and inconvenience themselves and for a scenario to be very hard for them, let's create something that revolves around them, that's create a patient centered, patient focused approach where we bring trials to patients in their homes.     00;14;05;21 - 00;14;28;07  And so we do this via some tools like apps on our phone and a mobile health platforms. We do this, of course, now via telehealth and things like that that have become much more routine and regular. We're able to collect data remotely. We're able to push out sort of questionnaires and quality of life and clinical outcome assessments to patients wherever they are.     00;14;28;11 - 00;14;53;23  We're able to send nurses to their home to help them administer drug or check on how they're doing or evaluate their symptoms. So this transition that COVID has sort of forced us into, again, necessity being the mother of invention has forced a more patient focused approach that I personally think we've been really long overdue. So I think of that as a little bit of a silver lining of the pandemic.     00;14;53;25 - 00;15;24;08  There's been some good progress, I think, made as a result of that. But these technologies that you're talking about that are used to monitor these patients in these trials, like maybe wearable technologies or whatever, what's the reliability level of that? Does a lot of this rely on the patient just reporting accurately what's going on? Well, as we've come out of the pandemic now, the interesting sort of dynamic is does this new model really stick around when it's not as needed as it was during COVID?     00;15;24;11 - 00;16;06;16  Do we continue to move forward in this new innovative approach, or do we revert back to the way it was? And along with that, are these sort of challenges maybe, and complications that come along with this decentralized approach, like remote data capture, lots of data sources coming from various areas, various directions, wearables, as you've said. And there's also this kind of push also to not only engage patients where they are, but also to collect data in a little bit of a real world setting in this, you know, real world evidence, real world data, you know, kind of concept around, you know, we're conducting clinical trials that are controlled and we're we're looking at specific variables     00;16;06;16 - 00;16;25;12  and we're looking to evaluate safety and efficacy. But at some point, if this new therapy is going to be approved and patients are are using this in their daily regular life, how it's better for us to also know what that's going to be like, like to study that real world experience now even in the context of a clinical trial.     00;16;25;12 - 00;16;44;27  And so you are even seeing regulators like the FDA encourage the collection of more real world data for that to be used to supplement more controlled clinical trial data. So you're having a little bit of a mixture here and a little bit of an evolution, I would say, in terms of the data and evidence that we're bringing in.     00;16;44;29 - 00;17;12;08  But your point, there's there's lots of challenges with that as well. Now we have a lot of different technology platforms. We have a lot of data sources that need to interface and communicate and integrate. There can be complexities with having lots of different technology platforms for clinical sites and patients to use. You mentioned the reliability component. Are we using instruments that are validated and have been used over and over and we can trust?     00;17;12;10 - 00;17;39;17  So with this new approach of collecting more data, collecting data from different sources, collecting real world data, we also have to make sure that we're integrating it well, that we're not overly burdening both the clinical sites and the patients. But the trend that we're seeing is that each year now, clinical trials become a little bit more complex. They're collecting more and more data each year.     00;17;39;20 - 00;18;10;11  Data points in these clinical protocols are becoming more extensive. Right? So, you know, that's more data that becomes a little bit more of a burden for a lot of people. And it also takes us back to this, this mantra of, okay, let's remember the patients again, because if you're going back to my example, if you're a scientist or a drug developer in a conference room in New Jersey, you may very well want to collect all kinds of interesting data points that you think are going to be informative to you.     00;18;10;11 - 00;18;41;03  And if everybody sort of pours in all their sort of data requests, you can see this sort of ballooning, mushrooming clinical trial becoming overly burdensome. And let's not forget that each of those measurements require something of a patient. So there needs to be some kind of balance here between gathering more data, real world evidence controlled clinical trial data, but also remembering that, you know, the patients are producing that data and let's not make things overly complicated here.     00;18;41;03 - 00;18;59;00  So there's a little bit of a dynamic there that I feel like we're right in the midst of it. I'm interested to see how this kind of plays out a little bit. Well, yeah, And that's being seen everywhere. There is a ton of data. Companies are drowning in data. Some of them know what to do with it, how to handle and process it, process it.     00;18;59;00 - 00;19;22;20  Some don't, but it is crucial. There are challenges and benefits to being data focused, especially where sensitive data is concerned. Things like evolving standards. I mean, is too much data a problem? Are these supposedly connected platforms causing redundancies and other headaches? Yeah, I mean, I think so. Probably depends on who you ask, right? I'm sure a lot of people would say more data, the better.     00;19;22;20 - 00;19;45;16  Let's get everything we can. It'll inform us better on a patient experience or on the effects of a drug. At the same time, though, right, there's logistical challenges. Where are these pipes of data running into in the while? It's happening across all kinds of industries in the clinical research, clinical drug development space, you also have the added piece of patient privacy.     00;19;45;19 - 00;20;11;07  And in this country, HIPA and the need to, you know, keep patients data safe, private, de-identified as well. So when you're implementing different platforms that are collecting data at a clinical site, but maybe also at a patient's home and also maybe a wearable as a patient is, you know, walking around and just their daily life and collecting data via that.     00;20;11;09 - 00;20;34;22  Where do these all come into? How are they getting analyzed? Is it secure? We can very easily and very quickly make things more complicated than we needed to. I personally think we should be mindful of not collecting every possible data point we might have an interest in. We might not even know what we want to do with that data today, but that might be nice to have down the road.     00;20;34;24 - 00;20;56;18  I do realize that's great for science and discovery and exploration, but again, in the context of a clinical trial, you know, the environment we're in right now with clinical trials is that more than 60% of all clinical trials are behind schedule due to enrollment. And even when patients do enroll, we also have a lot of patients dropping out and not staying on studies.     00;20;56;18 - 00;21;27;09  So the retention of patients is also a problem. And so while we balance collecting more data, while we balance more complicated, complex clinical protocols as we're increasing the burden at times on patients and I use this patient word a lot, but really we're talking about people, right? We're talking about people like like Mike and I who have jobs, who have lives, who have hobbies, who have families, work people, and we have other commitments in our lives.     00;21;27;09 - 00;21;50;24  And we can't just drop everything to participate in a clinical trial. So the the concept of if you build it, they will come doesn't really apply here really anymore. And we need to be thinking about building things that will appeal to people and be realistic and feasible for patients, both in terms of time, commitment and travel and there might be you know, there might be emotional issues.     00;21;50;24 - 00;22;14;12  There's all kinds of domains of burden that we've learned. And this balance of like, wow, we can collect data from anything anywhere, any time, that's great, but let's maybe we need to real that and a little bit here and balance that out with what can a human being really handle And are we overly burdening patients because we're finding that people are just declining to participate, which is actually.     00;22;14;14 - 00;22;40;16  So this idea of more data better can actually be slowing down drug development in a way because clinical trials are delayed now due to enrollment. So there's an interesting dynamic there that I think progress in this area, real world evidence, remote data capture, lots of data sources, is also creating a more complex environment that I think is giving giving some patients pause to like before and roll in that study.     00;22;40;16 - 00;23;09;24  I'm going to I'm going to think twice. So really interesting thing that's really very fluid and dynamic. I think this is kind of changing on a monthly basis these days. Well, let's turn back to rare diseases, because I think we can all agree plenty of innovation is needed to make a dent in those. But what kind of innovations and as I hear you talk, it's like, okay, there's challenges to this patient centered research, decentralized research as it is now.     00;23;09;24 - 00;23;37;12  You're talking about rare diseases where the population is small to begin with, it seems. I mean, what are the most effective things we could be doing? Is decentralized trials the answer? Yeah. Well, I think, you know, in that rare space, you're right, clinical trials are challenging. Clinical trials are behind schedule. Clinical trials might be overly complex. And I think that happens in worlds where we could be dealing with a fairly common, you know, diabetes or arthritis study.     00;23;37;14 - 00;24;03;10  When you overlay those challenges on a disease area and on a patient population, that is rare or ultra rare, you know, it becomes magnified, it becomes extra challenging. You know, some of those challenges include things like, well, by the nature of the name rare diseases, there's very few patients with that disease. Sometimes those patients and some of these disease states are very, very small.     00;24;03;12 - 00;24;25;08 And people are, of course, geographically spread out. So if you wanted to learn more about a disease, study it, run a clinical trial, what have you. You know, you're not just opening up a clinical center in New York City and enrolling all those patients. You might be needing to go to multiple countries around the globe just to be able to find a couple dozen patients.       00;24;25;10 - 00;24;50;26  So you've got a dispersed and few and far between patient issue is challenging to come to come up with. And again, by the nature of, you know, the definition, there are physicians and our principal investigators in clinical research sometimes don't see a lot of these patients. So for those of you listening that have that know a little bit about the rare disease space, you'll know that that's the symbol of rare diseases is the zebra.     00;24;51;02 - 00;25;13;17  And the reason for the zebra symbol is, you know, back in the fifties, there were some physicians that were training medical students, and they used to use the phrase that, you know, trying to teach their medical students that, you know, keep things simple, Don't overly think it don't overly complicated. If you think you're sort of stumbling upon a diagnosis, you're probably right.     00;25;13;17 - 00;25;34;13  So the phrase was, you know, if you hear hoof beats, it's probably a horse. Right. And the rare, rare disease community, of course, sort of shudders at that idea and says, well, hold on a second here. You know, if you hear hoof beats, don't forget that 10% of those diseases could be a zebra. Right. And the zebra or the rare disease has been one to not forget about.     00;25;34;13 - 00;25;55;17  So we we also have challenges with physicians that may come across a case or a patient like that once a year or once every couple of years. So there might be a limited knowledge about the disease and the care of those patients. It also makes those patients being diagnosed initially really, really challenging. I mentioned earlier the diagnostic odyssey.     00;25;55;19 - 00;26;19;18  It's not uncommon for a rare disease, patient or family to see seven, eight, nine, ten physician ones go to all kinds of different hospitals and institutions and have a variety of sort of tests done to figure out even what they have. Right. They're craving a diagnosis so they can figure out what's going on with them so that then they can start to think about how do I get this treated.     00;26;19;18 - 00;26;44;22  So there's there's challenges around diagnosis, There's challenges around how do you develop a drug in this new rare disease where clinical trials never been done before? What what are the end points? What kind of benefit do we need to see if it's a genetic or life threatening disease? Does that change our, you know, the the efficacy safety sort of ratio we're willing to accept?     00;26;44;22 - 00;27;10;07  Right. So whole bunch of challenges there in that space. Again, though, I think there's been amazing progress. We've even seen things like the FDA and other regulators be more flexible and encourage innovation. They realize it's hard in this area and, you know, there aren't that many patients and conducting clinical trials and finding those patients and collecting data is extra challenging and we're not going to get that much of it.     00;27;10;07 - 00;27;53;14  So I've seen the FDA be very flexible and responsive and kind of partnering and collaborating with industry to help because we all want to kind of move these therapies forward and help these patients. So lots and lots of progress, but extra challenges. And I think it really creates an environment here where the rare disease space has really been the tip of the spear, both with decentralized clinical trials, with maybe some of these remote data capture paradigms, because again, necessity being the mother of invention, just to just to manage to do this in the rare disease space does require us to think differently and approach things differently and be creative and I think the     00;27;53;14 - 00;28;13;25  success we're seeing in this space, I'm hoping that other parts of our industry see that and also can adopt a little bit of innovation in their own little areas as well. Well, I'm always looking for good stories. Do you have some examples of where patient driven data really changed the trajectory of drug discovery for a specific rare disease?     00;28;13;27 - 00;28;49;06  Well, there's been a lot of good examples of this patient focused approaches that we're talking about, this idea of get outside of that conference room bubble, incorporate the patient voice and perspective into your drug development just to the point of. So if you're developing a, you know, a drug and you have a clinical trial, you're looking at endpoints, you're looking to write to measure the effect of your drug on, say, some kind of performance factor, You know, when you look at how we're going to develop that, the FDA may want a certain endpoint that is validated and it's the gold standard.     00;28;49;06 - 00;29;21;15  And they're looking for industry to kind of measure that and hopefully exceed that in their trial. The drug developers and industry, you know, they're often thinking about what's more what's realistic. Does it take us five years to achieve that endpoint? Is there something that's sub or is there a surrogate, is there a biomarker? And then interesting, when you talk to patients, you know, you hear this a lot of diseases, well, we'll use what's called the six minute walk test, which has been talked about ad nauseum as a measure of a patient's sort of performance.     00;29;21;15 - 00;29;44;20  The how far can you walk in the six minute space? And if you have, you know, any kind of respiratory or cardiac condition or maybe even something neuromuscular going on, it really limits your ability to kind of perform and walk in that that test that's been used as a standard for a time that's very controversial, that, you know, the FDA is required at a Times or industry has wanted to pursue it.     00;29;44;23 - 00;30;06;14  And then when you actually sometimes talk to patients themselves and say, you know, they'll look at the endpoint in a trial as measuring and say, well, that's not really relevant to my life. You know, if I'm able to walk across my kitchen and reach my arms up and get something out of the cupboard, that would be a dramatic, meaningful benefit to me, right?     00;30;06;20 - 00;30;27;22  Just the ability to do that on a day to day basis would change my life. And is there a way to measure something there that's maybe a little bit more relevant for patients, but also balances out what our scientists and our regulators and our industry professionals want, I think is so there's often a dynamic there around what are we going to measure?     00;30;27;22 - 00;30;53;07  There might even you might even argue there's a there's another arm in there that's maybe our our payers, right. Are insurance companies, what are they wanting to see, What's the benefit there? Because this drug will cost something. So it can't just be safe and we think it works. Is it working enough? Is the cost benefit enough? So there creates multiple kind of perspectives on how do we measure the effectiveness and and from what from whose perspective are we measuring it.     00;30;53;07 - 00;31;18;16  So that's pretty interesting. You're seeing more and more, you know, even in FDA new drug review meetings, you're seeing patients come up to podiums and share their experience on the trial, share their experience on the difference this drug made. There's been a lot of, you know, in the muscular dystrophy space, it's a really challenging disease, and drug development has been exceedingly difficult.     00;31;18;16 - 00;31;39;16    So it's been a lot of interesting stories there around not only the six minute walk test, but also just hearing patient voices, hearing the impact a drug has had on a patient or a family or a child. And there's often some competing data here around, well, the seemed to work for patients, but it didn't hit the primary endpoint that we wanted it to.     00;31;39;16 - 00;31;59;15    Yet there's some benefit here and we end up in some kind of gray area. And it's been an interesting kind of discussion and dialog we see playing out in those areas. So yeah, kind of competing priorities in a way. How do we find like what works for everyone? Now I'm going to ask you to put on your Nostradamus hat and predict the future.     00;31;59;23 - 00;32;22;05  Thinking about how things are trending now, what role will patients have in the next ten years of drug discovery? Will it be a story of, Hey, we found better ways to do decentralized trials and involve patients and that? Or does it shift to, hey, most of this stuff is done in silico with AI and that's how we do our research.     00;32;22;07 - 00;32;48;27  Yeah, fascinating. Yeah, I think the patient focus, the emphasis on being patient focused and considering patients, I feel like, you know, ten, 12 years ago was a really novel concept. I think we've made incredible strides in that area to where that's not a foreign idea anymore. You still may have some some people in the industry questioning the value of that, or can patients really inform their disease?     00;32;48;29 - 00;33;10;17  You know, a lot of us think the patients are truly the experts in their space. And there's been a lot, I think, to be there's advance things that informed us a lot by including that patient voice, patient perspective, bringing patients and patient panels to the to have a seat in that New Jersey conference room I referenced. Right. To actually provide their input early.     00;33;10;17 - 00;33;34;19  We're starting to see that more and more. And I think that's having impact and progress on making sure that we're creating things that are feasible for patients. So, you know, my crystal ball here on my desk sees us continuing to do more and more of that. I think there's a nice trend. I think rare disease, again, has been a space where we've kind of led the charge with that out of necessity.     00;33;34;21 - 00;33;56;02  But I think you'll see that extend into most other therapeutic areas. It's logical, right? It's good science. Consider your end user. Consider the people you're trying to help. Make sure what we're building or delivering or or trying to execute works for the people. You know, it's our Apple. Our iPhone works for the people who are actually using it right?     00;33;56;04 - 00;34;21;25  So I think we're going to see more and more of that, the decentralized clinical trial sort of paradigm that popped up as a necessity as a solution during COVID, you know, really has been like the hot sort of term and topic in our industry for the last two years. Again, if you picture if you if you zoom out, you see an industry that is risk averse and has been conducting clinical trials the same way for several decades.     00;34;21;28 - 00;34;45;25  We have a pandemic, we adjust, we adopt some new technologies. You know, from where I sit, I see this pendulum swinging back toward the middle a little bit. I feel like decentralized clinical trials are being looked at, maybe with a little more scrutiny and skepticism. You know, was this something that we just had to do short term? Is there really value in doing things that way?     00;34;45;25 - 00;35;19;25  Is there really are a slide back to your earlier point, Mike, Are we are we making things more complicated at times? Right. When you start to think about a patient focused approach where we collect data remotely, where we have nurses visit a patient's home, where we have things on telehealth, maybe we go into a clinical site as well, kind of introduces a few more different variables, and it makes not only the data more complicated, but if you're a patient, you might suddenly have six, seven, eight touch touchpoints of Who do I contact?     00;35;19;25 - 00;35;40;10  Is that the is it the help desk for the app or is it my nursing group or is it the clinical site or is it the sponsor or the CRO? So we're I think we've made some things a little bit more complicated and I think some of the risk averse folks in our industry are sort of looking at decentralized clinical trials saying, I don't know about this.     00;35;40;10 - 00;35;58;15  I wonder if maybe we're going to this pendulum will swing back and maybe all clinical trials will have maybe a little bit of a DCT component in them, maybe a little bit of remote data capture, maybe a little bit of consent, maybe a little bit of telehealth, and maybe that'll be just kind of the way we do things.     00;35;58;17 - 00;36;15;28    And we won't be looking at a regular clinical trial or a full DC trial. It'll be a little bit maybe about a mixture would be my thought so, But I do think we're going to continue to emphasize patients more and more. I think there's value in that. I think it's important. I think it's the right way to operate and the right thing to do.     00;36;16;01 - 00;36;33;16  Again, I think in any kind of industry, right, you want to be paying attention to your to your customers, right. And thinking about what they need and what's realistic for them. And I think our industry has a long way to go still in that area. So but again, with my crystal ball, I'm encouraged. I'm excited about where we're headed.     00;36;33;19 - 00;36;54;21    Well, getting back to the technology, especially how researchers figure out what tools to use, making decisions like legacy on premises systems versus cloud, what do you see? Are there mostly hybrid strategies out there, or is everything moving to the cloud? What are the pros and cons of each? Well, I'm the strongest technical person when it comes to things like that.     00;36;54;21 - 00;37;15;18  I do tend to focus on how we can collect data with patients, and I do a lot with wearables and some of these mobile platforms. I mean, it feels like, you know, the people I talk to, it feels like the legacy and on premises systems are, you know, are going away. It feels like everyone's in the cloud. Granted, I don't know, Mike, I live in Seattle.     00;37;15;18 - 00;37;37;16    I have Microsoft and Amazon down the street from me, so maybe it's just a little bit of a a bias with where I am geographically, but it feels like the cloud is where everything is going. I'm sure there are some folks listening who know a little bit more about the details than me, but that's my take. Yeah, well, you have been a longtime partner of Oracle, and in fact, you were at the Oracle Health Conference in September.     00;37;37;18 - 00;38;07;16  You're often participating in Oracle Life Sciences webinars. And I guess this goes back to the question of, you know, what is the industry's role in this thing? What has it been like working with Oracle and what role do you see companies like that playing in clinical research and drug discovery? Yeah, well, it's been a great partnership working with Oracle, both working with folks like yourself and your colleagues, but also leveraging a lot of the good technology solutions that Oracle developed.     00;38;07;19 - 00;38;38;17    I think that, you know, not to be a broken record, but again, risk averse drug development industry here. I think that a lot of innovation can occur from organizations like Oracle all pushing forward new technology, new concepts, new approaches. I'm a strong believer that the innovation in the space occurs from, you know, technology companies, service providers, bringing new solutions to biopharma sponsors.     00;38;38;17 - 00;39;05;18  So Oracle's been a group like that that has moved forward with different electronic data capture systems, you know, sort of the regulatory safety database solutions, things like CTMS's, the platforms that are being created are making us more efficient, they're making us more effective When it comes to the trials themselves. They're allowing data to be captured and integrated better from lots of different sources.     00;39;05;21 - 00;39;29;15  We talked about those challenges to that. But I think the direction is is a really good positive one. So Oracle and, you know, organizations like Oracle, I think are the ones really driving that. They're the ones to be to present new bright, shiny objects, new innovative technology and new solutions to pharma, and to say this will help move things along faster for you.     00;39;29;15 - 00;39;52;05     And with the you know, what the pressures around, you know, right now, the pressures around fundraising, the pressures around firms, maybe like prior noticing different sort of compounds in their pipeline, the challenges in the industry right now, I think everyone's looking for better, smarter, faster solutions. And that's where I think some technology and some innovation can come in.     00;39;52;05 - 00;40;15;01   And I think that's where Oracle will continue to make a really, really strong difference. Well, embrace my own shortcomings as a host. I never assume I've properly picked my guests brains. So what are you thinking about most these days? What's the big question or challenge you think we're facing? Or maybe there's just something you think it's important for our brilliant listeners to know.     00;40;15;04 - 00;40;35;25  And oh boy, we've covered some really interesting topics around, you know, data being captured. Is there too much data out there? How do we integrate data from all these all these different sources? I feel like that is a that is a topic that won't be going away anytime soon. Right? That is something that I think we're going to struggle with for a while of.     00;40;35;28 - 00;41;16;22  We want to capture data from all these new sources. How do we manage it, integrate it, validated, keep it secure. And then, of course, when you have this group of data, we're seeing, of course, artificial intelligence and machine learning and all kinds of derivatives of that occurring with really every data set we have. So that's I think the other big piece is how do we how do we as we collect more and more data, what kind of systems do we have built that are going to help us learn from that and inform us and hopefully within the context of clinical trials and drug development, all of the data we're collecting should allow us to design     00;41;16;22 - 00;41;44;25  the next trial better for the next one to be a little more smarter, to be a little more efficient or a little faster applying this. Maybe upstream into some of the drug discovery pre-clinical stages when we're really looking at new drug candidates, what might work? I think being able to leverage that data and be smart and inform ourselves to be able to accelerate drug to drug discovery in drug development.     00;41;44;28 - 00;42;12;15    I'm hoping that that's where we see great progress, because there are patients out there that really can't wait. And their only hope is that new therapy coming from a clinical trial. And right now, our process just takes a long time. So to that point, do you think do you think A.I. is overhyped? Like if I'm someone with a rare disease and I'm hearing about A.I. and I think, Oh, this is it, this is going to get the therapy or the drug treatment I need in the next year.     00;42;12;16 - 00;42;34;01  Yeah, I think I think that you should be realistic, right? I think that, you know, the AML is going to be those are going to be sort of tools and approaches that are going to be a big part of, like you said, probably most industries and our daily life everywhere. I don't know if that's going to be, you know, a magic bullet that is suddenly going to, like, revolutionize drug development overnight and move things along in a year.     00;42;34;09 - 00;42;53;17    I would temper expectations probably a little bit, but I'd be hopeful that this will help us and this will help us move faster and be smarter. But yeah, maybe that's not a maybe that's not a silver bullet that fixes everything. I think that's another tool in our arsenal to kind of move things forward faster. Well, Scott, thanks again for your time today.     00;42;53;19 - 00;43;15;07  If anyone wants to learn more about you or what you've talked about or a rare clinical, what's the best way for them to do that? Yeah, absolutely. It's been my pleasure to be here today. I've really enjoyed it. Really enjoyed the topics in the conversation. You know, my email address, I guess will put an email out. There is a Scott Schliebner – I'll spell out Schliebner     00;43;15;12 - 00;43;40;19  @ msn.com. You can also find me on LinkedIn. Scott should leave her and be happy to engage, support, help you out there in any way that I can. Great. We appreciate that. If you are interested in how Oracle can accelerate your research and data needs, all you have to do is check out Oracle dot com. And join us again next time for research and action. 

Ezt is megbeszéljük újságírónkkal, aki igyekszik lépést tartani velük.

In this podcast, our Medical Director, Dr. Brad Lewis, discusses heparin-induced thrombocytopenia, also known as HIT. Dr. Lewis addresses what HIT is, how to diagnose and interpret testing, and the role of functional testing like the HIPA (Heparin-Induced Platelet Antibody) test.

A wee update on why we've been so quiet. HIPA working group's guides for freelancers and organisations – navigating sexual harassment at work. harassment-in-the-performing-arts-guides-for-freelancers-and-organisations/ OUR WEBSITE - www.persistentandnasty.co.uk Persistent Pal & Nasty Hero - Pals and Hero Membership Support In The Room - https://www.crowdfunder.co.uk/p/in-the-room Email – persistentandnasty@gmail.com Instagram - @persistentandnasty Twitter - @PersistentNasty Coffee Morning Eventbrite - Coffee Morning Tickets LINKTREE - LINKTR.EE Resources Samaritans - Rape Crisis Scotland - Rape Crisis UK ArtsMinds - BAPAM Freelancers Make Theatre Work Stonewall UK - Trevor Project - Mermaids UK Switchboard LGBT+ - GATE PLANNED PARENTHOOD DONATE - DONATE ABORTION SUPPORT NETWORK UK - ASN.COM- DONATE WeAudition offer: For 25% off your monthly subscription quote: NASTY25 Backstage Offers: Get a free 12 months Actor Subscription: https://join.backstage.com/persistentnasty-uk-12m-free/

Paul Nicklen has documented the beauty and plight of our planet for more than twenty years. His work is collected by Hollywood icons, rock stars and royalty. In 2019, he became the youngest person inducted into the International Photography Hall of Fame. He has said it is one thing to capture the natural world in a moment of grace and dignity, but that pales in comparison to an image that shines a brighter light on the environmental crisis and drives everyday people to action, even if only in some small way. His work has been singled out for creating a unique connection between image and viewer by featuring wild subjects in some of the most extreme conditions known on Earth.  He is a Sony Artisan of Imagery and aligns with Rolex's Perpetual Planet initiative on collaborative efforts to preserve the natural world. Nicklen has won more than thirty of the field's most prestigious awards, including the BBC's Wildlife Photographer of the Year, and the World Press Photo for Photojournalism. He has exhibited in galleries, museums and institutions around the world, including Hilton Asmus Contemporary (Chicago), Lyons Gallery (Australia), Galerie Gadcollection (Paris), Eisele Gallery (Cincinnati) and Fineart Oslo (Oslo).  Cristina Mittermeier was born in Mexico City in 1966. She graduated from the ITESM University in Mexico with a degree in Biochemical Engineering in Marine Sciences. She later attended the Fine Art Photography program at the Corcoran College for the Arts in Washington, D.C. She was named one of National Geographic's Adventurers of the Year in 2018. Her Photographs have been exhibited in galleries around the World, including Hilton Asmus (Chicago), the Saatchi Gallery (London), C. Parker Gallery (Greenwich), and Eisele Gallery (Cincinnati).  She is currently preparing for a solo exhibition at the prestigious Gallerie d'Italia in Turino, Italy. Mittermeier's many awards include the Smithsonian Conservation Photographer of the Year; the Humanity Content Creator Award from HIPA; the Imaging Award for Photographers Who Give Back; the Seattle Aquarium's Sylvia Earle Medal; Travel + Leisure's Global Vision Award, and was named one of the “100 Latinos Most Committed to Climate Action.” She is a World Photographic Academy member; was the first female photographer to reach one million followers on Instagram; is a Sony Artisan of Imagery; and aligns with Rolex's Perpetual Planet initiative on collaborative efforts to preserve the natural world. EXHIBITION: “Double Exposure: Two Photographers, One Mission” at C. Parker Gallery features more than 30 large-scale photographs by Nicklen and Mittermeier (on view May 1 ‒ June 26, 2013) at the C. Parker Gallery in the Greenwich, Connecticut area. Cristina Mittermeier & Paul Nicklen ONLINE: www.SeaLegacy.org  JONES.SHOW Online:    Join us in the Jones.Show Lounge on Facebook. Twitter (Randy): https://twitter.com/randallkjones  Instagram (Randy): https://www.instagram.com/randallkennethjones/ Facebook (Randy): https://www.facebook.com/mindzoo/ Web:  RandallKennethJones.com Twitter (Susan): https://twitter.com/SiriouslySusan Instagram (Susan): https://www.instagram.com/siriouslysusan/ Facebook (Susan): https://www.facebook.com/siriouslysusan/ Web: SusanCBennett.com LinkedIn (Kevin): https://www.linkedin.com/in/kevin-randall-jones/ Web: KevinRandallJones.com  www.Jones.Show

Fourteen year old Hipa Tuhipa, who lives with Autism Spectrum Disorder, has won two gold medals for Niue at the Oceania Powerlifting Championship, senior sport journalist Iliesa Tora interviews Hipa and his parents.

Artist bio https://www.cristinamittermeier.com Instagram: @Mitty     Cristina Goettsch Mittermeier, "Mitty", was born in Mexico City in 1966 and grew up in nearby Cuernavaca, in the sunny state of Morelos. Hailed as one of the most influential conservation photographers of our time, she has dedicated her entire life to protecting the World's oceans - inspiring millions of people to do the same.  She graduated from the ITESM University in Mexico with a degree in Biochemical Engineering in Marine Sciences. She later attended the Fine Art Photography program at the Corcoran College for the Arts in Washington, D.C. She has three adult children, John, Michael and Juliana, all of whom are passionate about nature. She lives on Vancouver Island, in British Columbia, Canada.   In 2005 Mittermeier founded the prestigious International League of Conservation Photographers (ILCP) to provide a platform for photographers working on environmental issues and coined the phrase "conservation photography".   In 2014 she co-founded SeaLegacy, a non-profit organization using strategic communications at the intersection of art, science, and conservation to protect and rewild the ocean for the benefit of biodiversity, humanity, and climate within our lifetimes.        “Images can help us understand the urgency many photographers feel to protect wild places. My work is about building a greater awareness of the responsibility of what it means to be human. It is about understanding that the history of every living thing that has ever existed on this planet also lives within us. It is about the ethical imperative—the urgent reminder that we are linked to all other species on this planet and that we have a duty to act as the keepers of our fellow life forms.”       Cristina's work has published in hundreds of prestigious magazines, including National Geographic, TIME, McLean's, The Men's Journal and O. Along with her partner, Paul Nicklen, she was named one of National Geographic's Adventurers of the Year in 2018, and in 2021, she was featured in Welcome to Earth on Disney+.  Cristina is honoured with many prestigious awards, including the Smithsonian Conservation Photographer of the Year Award, the Humanity Content Creator Award from HIPA and the Imaging Award for Photographers who Give Back. In 2021, she received the Seattle Aquarium's Sylvia Earle Medal and Travel + Leisure's Global Vision Award and was named one of the 100 Latinos Most Committed to Climate Action. Additionally, she is a World Photographic Academy member and the first female photographer to reach 1 million followers on Instagram.   Cristina is a committed impact investor and an influential voice in bridging financial returns while creating a positive social and environmental impact. 

Artist bio https://www.cristinamittermeier.com Instagram: @Mitty     Cristina Goettsch Mittermeier, "Mitty", was born in Mexico City in 1966 and grew up in nearby Cuernavaca, in the sunny state of Morelos. Hailed as one of the most influential conservation photographers of our time, she has dedicated her entire life to protecting the World's oceans - inspiring millions of people to do the same.  She graduated from the ITESM University in Mexico with a degree in Biochemical Engineering in Marine Sciences. She later attended the Fine Art Photography program at the Corcoran College for the Arts in Washington, D.C. She has three adult children, John, Michael and Juliana, all of whom are passionate about nature. She lives on Vancouver Island, in British Columbia, Canada.   In 2005 Mittermeier founded the prestigious International League of Conservation Photographers (ILCP) to provide a platform for photographers working on environmental issues and coined the phrase "conservation photography".   In 2014 she co-founded SeaLegacy, a non-profit organization using strategic communications at the intersection of art, science, and conservation to protect and rewild the ocean for the benefit of biodiversity, humanity, and climate within our lifetimes.        “Images can help us understand the urgency many photographers feel to protect wild places. My work is about building a greater awareness of the responsibility of what it means to be human. It is about understanding that the history of every living thing that has ever existed on this planet also lives within us. It is about the ethical imperative—the urgent reminder that we are linked to all other species on this planet and that we have a duty to act as the keepers of our fellow life forms.”       Cristina's work has published in hundreds of prestigious magazines, including National Geographic, TIME, McLean's, The Men's Journal and O. Along with her partner, Paul Nicklen, she was named one of National Geographic's Adventurers of the Year in 2018, and in 2021, she was featured in Welcome to Earth on Disney+.  Cristina is honoured with many prestigious awards, including the Smithsonian Conservation Photographer of the Year Award, the Humanity Content Creator Award from HIPA and the Imaging Award for Photographers who Give Back. In 2021, she received the Seattle Aquarium's Sylvia Earle Medal and Travel + Leisure's Global Vision Award and was named one of the 100 Latinos Most Committed to Climate Action. Additionally, she is a World Photographic Academy member and the first female photographer to reach 1 million followers on Instagram.   Cristina is a committed impact investor and an influential voice in bridging financial returns while creating a positive social and environmental impact. 

Nick Hipa is a guitarist and songwriter who has played with As I Lay Dying, God Forbid, Mire, and Wovenwar.  On this episode: Nick's approach to learning the God Forbid set What Nick obsesses over  The differences between As I Lay Dying, Wovenwar, and Mire Going indie vs signing to a label Saving riffs The Zakk Wylde speed trick Watching Eddie Van Halen from side stage Musical vs life priorities Training your creativity Want to level up your guitar game? Check out Riffhard. When you sign up, you'll get access to: Over 100 video tutorials with tabs A chance to enter our monthly King Of The Riff contest Livestream Q&As and other events Our private community Be sure to follow Riffhard on Instagram and Facebook. Follow Eyal Levi on Instagram. Follow John Browne on Instagram. Like this show? Please leave us a 5-star review - even one sentence helps! Learn more about your ad choices. Visit megaphone.fm/adchoices

Doc welcomes former As I Lay Dying guitarist, Nick Hipa, to the show, and they talk about how Nick got his start in Texas with band Evelynn, how that led him to join As I Lay Dying, how the band focused on improving their chops and songwriting through the years, experiencing big success, his thoughts on the metalcore subgenre, what it was like starting over with Wovenwar, learning video design as a second career, his experience as an independent artist launching his new band MIRE, the secret to his health and positivity, and how he has enjoyed playing with God Forbid This episode features the songs "The Prison We Make It" by Grey March and "In Fear" by MIRE. Follow Nick on Instagram @NickHipa and Twitter @yesTHEnickhipa Follow Doc on Instagram and Twitter @DocCoyle Please support this show's sponsor Grey March at https://distrokid.com/hyperfollow/greymarch/social-disease-2 Listen to more great podcasts like this at soundtalentmedia.com Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Come hangout with El Parcero Philly as we discuss Philly Sports! We discuss: - Eagles Christmas Eve loss - Sixers Christmas Day win - Phillies offseason - World Juniors - Gazdag Extension? Check it out! Make sure you guys check out our sponsor for the show, our friends over at La Touraine Watches! Check out their great selection of watches, make sure you use the promo code "ParceroPhilly" for 10% your purchase! https://la-touraine.com Subscribe: https://www.youtube.com/channel/UC7ar...... Follow Me! Twitter: https://twitter.com/ParceroPhilly ... Instagram: https://www.instagram.com/el_parcero_...... Tik Tok: https://www.tiktok.com/@elparcerophil......

On this episode Ariel is joined by returning guest Laura LeDoux about a serious issue, that what you don't know can hurt you. Women's FemTech data can be used against them, this is something you should know about so you can tell your families and friends. Ida Tin coined the term FemTech. She is the Co-Founder of Clue, a women's health tracking app. FemTech has grown to encompass a range of technology-enabled, consumer-centric products and solutions. Other examples of women's healthcare apps are: Nurx (birth control delivery); Khair (tracking your period, pregnancy, speaking to a doctor); Sexual Activity Log and Tracker (this includes birth control information as well as sexual activity); Ease (birth control reminders), and Unified Women's Healthcare. The Griswold versus Connecticut case was the Supreme Court case that first gave women the right to contraception in the United States in 1965, making the prevention by states of the use of contraception by married couples illegal in 1965. https://supreme.justia.com/cases/federal/us/381/479/  States that ban abortion are: Alabama, Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, Oklahoma From: https://www.google.com/search?q=states+that+ban+abortion&rlz=1C1CHZN_enUS1020US1027&oq=states+that+ban+&aqs=chrome.1.69i57j0i512l9.7504j0j4&sourceid=chrome&ie=UTF-8  Interactive map of abortion laws in the U.S.: https://www.nytimes.com/interactive/2022/us/abortion-laws-roe-v-wade.html  Some states that have restricted access to contraception funds are: Arizona, Arkansas, Colorado, Indiana, Iowa, Michigan, Mississippi, Missouri, Nebraska, New Hampshire, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, Texas and Wisconsin, according to the Guttmacher Institute. From: New Research Shows State Restrictions Reduce Contraception Use by Christine Vestal, 9/22/22,  Pew Charitable Trusts, https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2022/09/22/new-research-shows-state-restrictions-reduce-contraception-use  Megan Kavanaugh, principal research scientist at Guttmacher, said,“Given the increased restrictive climate around abortion in our country, we are anticipating amped-up attacks on contraceptive access, as both of these are efforts that target people's reproductive autonomy and freedom,” she added. Guttmacher's research describes the change in contraceptive use that occurred after Iowa opted out of a Medicaid family planning program in 2017 and set up its own state-funded contraception program, which excluded clinics that provided abortion along with other health services. The study found that the share of patients at publicly funded family planning centres in Iowa who had not recently received contraceptives increased from 32% to 62% over two years. The share of patients not using any contraceptive method increased from 9% to 15%. Roughly 50 million, or 65% of women of reproductive age, 15-49, used some form of contraception from 2015 to 2017, the federal Centers for Disease Control and Prevention says. According to the Kaiser Family Foundation, 1 in 3 low-income people who use contraception rely on Planned Parenthood or other publicly funded clinics to pay for the often-costly pills or devices. Medicaid, which covers about 70 million individuals, is the largest funding source for free contraception. Another federal program, Title X, provides additional funds to roughly 4,000 clinics across the country to support access to contraception. During the Trump administration, those funds were withheld from Planned Parenthood and other clinics that provide abortion. In July, the U.S. Department of Health and Human Services issued a reminder to insurance companies that birth control, along with other preventive care, must be covered under the Affordable Care Act at no cost.  The agency said the action was part of a Biden administration effort to protect women's access to contraception in the wake of the U.S. Supreme Court decision that eliminated the longstanding federal right to abortion. “Under the ACA, you have the right to free birth control — no matter what state you live in,” HHS Secretary Xavier Becerra said in a statement. “With abortion care under attack, it is critical that we ensure birth control is accessible nationwide, and that employers and insurers follow the law and provide coverage for it with no additional cost.” From https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2022/09/22/new-research-shows-state-restrictions-reduce-contraception-use   What can women do to be proactive with their data privacy and security and their healthcare apps? Protect your data Use enhanced protection, especially if you're in a state that does not protective women's reproductive rights, e.g. Pseudonyms Having sensitive conversations orally instead of over text/email/apps Be aware that deleting data does NOT make it unavailable to law enforcement Don't post personal health conditions on social media Lobby your local lawmakers to enhance data privacy laws at the state level to protect healthcare data shared over apps In extreme cases, move to a state that honours and protects women's reproductive rights. The Fourth Amendment of the U.S. Constitution is also affected by the Roe decision.  "The right of the people to be secure in their persons, houses, papers, and effects, against unreasonable searches and seizures, shall not be violated, and no Warrants shall issue, but upon probable cause, supported by Oath or affirmation, and particularly describing the place to be searched, and the persons or things to be seized." From https://constitution.congress.gov/constitution/amendment-4/  KEY TAKEAWAYS FemTech is something that's at the forefront of technology in general and specifically technology to do with women's health. It provides solutions to improve healthcare for women across a number of female-specific conditions including maternal health, menstrual health, pelvic health, sexual health, fertility, menopause, contraception, other general health conditions that affect women disproportionately such as osteoporosis or cardiovascular disease. It also affects the transgender community as well. There is no Federal protection for women's reproductive rights. The Dobbs Decision has now left that to each individual state. You may have certain rights in ‘x' state and then you move into ‘y' state and now you no longer have those same rights. Health data that's collected by a health provider, like a hospital or doctor's office, is protected by a Federal law called HIPA (Healthcare Information Privacy Act). HIPA doesn't apply to data collected by a healthcare app, for example, that you're using to track your menstrual cycle because you're trying to get or avoid getting pregnant. That data is protected by whatever state law is in effect with regards to data privacy in general. The upsides of FemTech are that it creates apps, and virtual and digital space that improves care delivery with virtual clinics, direct to consumer prescription delivery – including the morning after pill – it enables self-care through tracking diagnostics, it improves diagnostics, it addresses stigmatised topics such as menstrual health, sexual health and pelvic care. It delivers culturally sensitive and tailored care for frequently marginalised communities, it also opens up healthcare and certain types of healthcare that maybe weren't able to be physically present in neglected communities. It's really been a catalyst for positive changes in healthcare. But now, with the collapse of privacy protections after Roe vs Wade we really need to be proactive in making sure we're being vigilant about our own data privacy and security when using FemTech apps and what kinds of conversations we're having over text messages. BEST MOMENTS “Women's health rights have always been important, but they've never been more important than they are now in the wake of the Dobbs Decision.” “If aggressive states can utilise this data in any way to prove that somebody may have intentionally miscarried, then they can file criminal charges against those women.”“There are now cases where women are having defence attorneys in the emergency room with them to protect them if they're having a miscarriage.”“State like Texas don't have any exceptions for rape or incest. It's horrifying.” ABOUT THE GUEST Laura LeDoux, Esq., CIPP/US provides trusted program management and policy guidance in the Information Security space Laura leverages her legal acumen and expertise in information security, data privacy and compliance to help clients achieve their goals while staying compliant with applicable laws and regulations. Laura liaisons with technical and legal professionals from around the world to deliver innovative solutions that merge legal and technical requirements to ensure end-to-end compliance.  Socials: If you want to connect with Laura LeDoux, please add her on LinkedIn at  https://www.linkedin.com/in/lauraledoux/ or reach out to Ariel.  ABOUT THE HOST Ariel is a Licensed Massage Therapist, Registered Clinical Hypnotherapist, Reiki Master, Empath and Psychic who has been involved in holistic healing since 1988. She is also an educator, speaker, author and mentor for empaths, spiritual seekers and medical professionals. To reach Ariel, go to www.arielhubbard.com, where you will be able to contact her directly.  Please let her know you heard her on the podcast and the assistance you need or question you have. Website: www.arielhubbard.com Online Courses: http://hubbardeducationgroup.myclick4course.com LinkedIn: @arielhubbardIG: @arielhubbardFacebook: @HubbardEducationGroupYT: @arielhubbardCH: @arielhubbard Pinterest:   https://pin.it/6Z6RozS Pre-order form for Ariel's educational, hilarious and spicy dating book: The Empowered Woman's Guide to Online Dating: Set Your BS Tolerance to Zerohttps://eworder.replynow.ontraport.net/ See omnystudio.com/listener for privacy information.

Colabora Con Biblioteca Del Metal: En Twitter - https://twitter.com/Anarkometal72 Y Donanos Unas Propinas En BAT. Para Seguir Con El Proyecto De la Biblioteca Mas Grande Del Metal. Muchisimas Gracias. La Tienda De Biblioteca Del Metal: Encontraras, Ropa, Accesorios,Decoracion, Ect... Todo Relacionado Al Podcats Biblioteca Del Metal Y Al Mundo Del Heavy Metal. Descubrela!!!!!! Ideal Para Llevarte O Regalar Productos Del Podcats De Ivoox. (Por Tiempo Limitado) https://teespring.com/es/stores/biblioteca-del-metal-1 As I Lay Dying es una banda estadounidense de metalcore formada en el año 2000 en San Diego, California. El nombre de la banda deriva del libro Mientras agonizo (en inglés As I Lay Dying) del autor William Faulkner A pesar de que sus integrantes son seguidores de la doctrina cristiana, la banda no toca temas relacionados con sus creencias religiosas y los integrantes han insistido en que no son una banda de culto cristiano. En mayo de 2013 su líder, Tim Lambesis, fue arrestado por el intento de contratar a un sicario para asesinar a su exmujer Lambesis fue liberado de prisión en libertad condicional en diciembre de 2016. La banda se reformó en 2018 con el lanzamiento de su nueva canción "My Own Grave", que incluía a todos los miembros antes de la pausa indefinida. Lanzaron su séptimo álbum de estudio, Shaped by Fire, el 20 de septiembre de 2019. Después de dejar la banda Society's Finest, donde tocaba la guitarra el vocalista Tim Lambesis, formó As I Lay Dying en 2000. Comenzó como un dúo con el baterista Jordan Mancino, después se reunieron por primera vez como una banda en febrero de 2001, el nombre de la banda fue tomado de la novela del mismo nombre de William Faulkner, aunque no existe una correlación entre la música de la banda y el tema del libro. Tim Lambesis declaró en una entrevista en metalunderground que, "Tenemos la idea del nombre. Yo no diría que existe una correlación en el sentido del libro y el significado de la banda. Nos robaron el nombre a partir de ahí". La discográfica Pluto Records se interesó y ofreció AILD un contrato de grabación. Un mes después de aceptada la oferta, la banda entró al estudio de grabación para grabar su primer álbum con el nombre Beneath the Encasing of Ashes, que fue lanzado en junio de 2001. La banda se dio cuenta de que era necesario un guitarrista más y un bajista. Mancino comentó que "empecé a ir de gira y nosotros necesitabamos, evidentemente, un mayor número de integrantes de lo que eramos’’. Dado que no tenían "sólidos integrantes", además de los miembros de Tim Lambesis y Jordan Mancino, la banda invitó a sus amigos a tocar con ellos, por lo que la banda sufrió varios cambios en su formación. Noé Chase bajista dejó la banda en 2001, Brandon Hayes y su posterior reemplazo Aaron Kennedy se fue en 2003, poco después de la formación de la banda de Tokio Smash en Tulsa, Oklahoma. El contrato de As I Lay Dying con Pluto Records había expirado y la banda ya podía buscar otros sellos discográficos. Después de extensas giras y un aumento de la popularidad, Metal Blade Records les ofreció un contrato en marzo de 2003. La banda aceptó la oferta y el titular de Pluto Records, Brian Cobbel, estaba a favor de pasar la banda a Metal Blade. Lambesis comentó "ya hemos estado en la etiqueta, que realmente ha pasado fuera de su mercado de manera de diferente de lo que nos ha comercializado otras bandas en el pasado y nos han empujado realmente como una nueva etiqueta para el sonido." En julio de 2003, la banda saco su segundo álbum de estudio, Frail Words Collapse. Producido por Lambesis, el álbum alcanzó el número 30 en el Top Discos Independientes, y el número 41 en el Top Heatseekers. Seguido de una gira para promover el álbum con las bandas Himsa, Shadows Fall, The Black Dahlia Murder, Killswitch Engage, In Flames. Los Vídeos musicales de las canciones "94 Hours" y "Forever" Fueron transmitidos por Fuse y en MTV2 Headbanger's Ball. As I Lay Dying entró al estudio de grabación Big Fish en Encinitas, California, en enero de 2005 parar grabar su tercer álbum de estudio. Shadows are Security fue lanzado en junio, y debutó en el número 1 en el Top Discos Independientes. Fue la primera vez que la banda entró en el Billboard 200 en el número 35, y vendió cerca de 275 000 ejemplares. Wade Kergan de Allmusic lo llamó "uno de los más pesados del 2005," y comentó que los nuevos guitarristas Phil Sgrosso y Nick Hipa, hacían la banda "más pesada". El guitarrista Evan White había dejado la banda por motivos personales después de que su madre falleciera. Todas las voces limpias eran cantadas por Dave Arthur of Kings, ya que sonaba en el estudio un poco más poderoso que Clint Norris. El guitarrista Phil Sgrosso grabó las pistas del bajo en el álbum, para obtener el registro acabado en el momento dado. As I Lay Dying comenzó una gira para promover el nuevo disco, haciendo presentaciones en el Hell on Earth, Winter Headline Tour, Ozzfest, y una gira con Slipknot y Unearth. La banda estaba en la segunda etapa, junto con Rob Zombie, Killswitch Engage, Mastodon, It Dies Today. En la tasa de 75.000 dólares de la banda podría haber elegido para llevar a cabo en la etapa Headliners pero rechazó la oferta, ya que pensaba que no vale la pena el dinero. El grupo elevó su perfil en el año 2006 a través de su espacio de apoyo en el Taste Of Chaos de gira en los EE. UU. junto a bandas como Deftones, Thrice, Dredg, Funeral for a Friend y Story of the Year. En el verano de 2006, As I Lay Dying cierra con el Sounds of the Underground Festival. En mayo de 2006, Beneath the Encasing of Ashes y las canciones del split con American Tragedy fueron re-lanzados como: A Long March: The First Recordings a través de Metal Blade Records. El re-lanzamiento alcanzó el número 3 en el Top Discos Independientes, y 129 en el Billboard 200. El bajista Clint Norris dejó la banda en buenos términos en noviembre de 2006 con el deseo de centrarse en su matrimonio. La banda audicionó diez bajistas, aunque sin éxito. Lambesis había recibido cintas demo de una banda llamada This Endearing, con el bajista Josh Gilbert. Lambesis quería "formar parte de él" y esperar a que la banda para grabar más material. Sin embargo, This Endearing se separó y Gilbert fue reclutado como nuevo bajista. En 2007, As I Lay Dying comenzó a grabar un nuevo álbum titulado An Ocean Between Us, que fue puesto en venta el 21 de agosto de 2007. Debutando en el número 8 en el Billboard 200 y número 1 en el Top Rock gráfico con la primera semana de ventas de 39.000, el álbum fue el más alto de cartas de ventas de la banda. Coproducido por el guitarrista de Killswitch Engage Adam Dutkiewicz, y mezclado por Colin Richardson, el álbum recibió críticas generalmente positivas. Christa L. Titus de Billboard comentó: "Independientemente de las diferencias entre AS I LAY DYING personal cuáles son sus deseos y la demanda de los fans, este álbum seguramente actúa como un puente ", alabando la canción" Confort Betrays "para su solo de guitarra. Scott Alisoglu de Blabbermouth.net describe el álbum como" un bien redondeadas y con frecuencia thrash y metalcore álbum, ya que la banda ha logrado un equilibrio eficaz entre la agresión melodías y accesible. " Thom Jurek de allmusic elogió la banda musical para ampliar su gama con la inclusión de coros y melódica voz limpia, como se había hecho en Confined de Shadows are Security. Este álbum se argumenta por parte de algunos de ser más de un thrash y heavy metal, disco, y menos de un álbum de metalcore Frail Words Collapse y Shadows are Security, aunque algunos elementos de metalcore todavía brillan a través de. Es el primer álbum con el bajista Josh Gilbert.. Para promocionar el álbum, As I Lay Dying realizó una recital en el Warped Tour 2007 en agosto, y una gira por Europa en septiembre con Darkest Hour, Himsa, y Maroon. La banda fue premiada con el "Ultimate metal God" por la MTV2 "All That Rocks", y fue nominado para un premio Grammy en la categoría de " Best Metal Performance " por la canción "Nothing Left". Otros nominados incluyen Slayer (que ganó el premio), King Diamond, Machine Head, y Shadows Fall. Que desempeñaban algunos de los Warped Tour 2008, así como the Taste of Chaos Tour 2008. El 9 de abril de 2009, su DVD titulado " This Is Who We Are " fue lanzado en los Estados Unidos. El 14 de abril de 2009, el DVD fue lanzado en Europa. As I Lay Dying escribió como 6 o 7 canciones hacia el 28 de septiembre de 2009 para su nuevo álbum, y entró a estudio para comenzar a grabar a mediados de octubre. El 23 de noviembre de 2009, Josh Gilbert anunció a través de Twitter que la mitad del disco estaba grabado. El disco se tituló The Powerless Rise y la fecha de lanzamiento del disco fue el 11 de mayo de 2010. El 8 de noviembre de 2011, As I Lay Dying lanzó el álbum titulado "Decas" por motivo de los diez años de la banda. Este disco incluye tres nuevas canciones, cuatro covers, una canción re-grabada y cuatro re-mix. Además a través de iTunes se puede descargar el re-mix de la canción "Upside Down Kingdom". En enero de 2012, As I Lay Dying entró en el estudio con el productor Bill Stevenson (NOFX, Rise Against, Anti Flag) y comenzó a trabajar en el material de su sexto álbum. El 25 de enero, se anunció que se presentará el Mayhem Festival 2012 con Slipknot, Slayer, Motörhead, Anthrax, The Devil Wears Prada, Asking Alexandria, Whitechapel, Upon A Burning Body, I The Breather, Betraying the Martyrs y Dirtfedd. El 22 de junio, la banda anunció en el Metal Blade Records sitio web que su sexto álbum se titulará "Awakened" y está listo para el lanzamiento el 25 de septiembre. El primer sencillo del álbum, "Cauterize", fue lanzado el 25 de junio. Fue puesto a disposición en el sitio web de la banda como una descarga gratuita durante 24 horas y luego puede adquirirse el día después. La banda entró en una pausa indefinida en 2014 cuando Lambesis fue encarcelado y condenado a seis años de prisión por contratar a un sicario para matar a su exmujer. Los miembros restantes formaron una nueva banda con el cantante de la banda Oh, Sleeper, Shane Blay, el resultado de esta unión es la banda llamada Wovenwar. En 2016, Mancino hizo una entrevista discutiendo principalmente Wovenwar, pero también habló de As lay Dying. [6] Él declaró que, contrariamente a la creencia popular, que Hipa, Sgrosso y Gilbert son todavía técnicamente una parte de As I Lay Dying debido a su contrato de grabación. Lambesis fue liberado de prisión en libertad condicional en diciembre de 2016. En el día del padre 2017, la página de Facebook de la banda hizo una publicación con solo una palabra, "Activity", posiblemente indicando que la banda podría estar regresando. [55] El 2 de septiembre de 2017, Metal Injection informó que Tim Lambesis estaba trabajando en música nueva y planeaba lanzarla bajo el nombre de As I Lay Dying, asumiendo que ninguno de los miembros anteriores volverá, incluido Mancino, lo que convertiría a Lambesis en el único miembro restante de la banda desde su formación en 2000. Sin embargo, el 8 de junio de 2018, la banda lanzó un nuevo videoclip musical de su nueva canción "My Own Grave" donde se aprecia el regreso de la alineación clásica de la banda con todos sus integrantes. El 12 de abril de 2019, la banda lanzó un video musical para Redefined, que incluyó una aparición especial del líder de August Burns Red, Jake Luhrs. El 14 de abril de 2019, la banda anunció la gira "Shaped by Fire" de Europa con el apoyo de Chelsea Grin, Unearth y Fit for a King, que se extenderá desde septiembre de 2019 y concluirá en octubre. [78] [79] El 15 de julio de 2019, la banda anunció las fechas norteamericanas de la gira "Shaped by Fire" con el apoyo directo de After the Burial y Emmure, que comenzarán el 15 de noviembre en House of Blues en Las Vegas y concluirán el 14 de diciembre con un espectáculo de la ciudad natal en el Soma San Diego. Los detalles de su próximo álbum, Shaped by Fire, se filtraron a través del sitio web europeo de Nuclear Blast con una fecha de lanzamiento prevista para el 20 de septiembre de 2019. El 9 de agosto de 2019, la banda anunció oficialmente que su primer álbum en siete años, Shaped by Fire, se lanzaría a través de Nuclear Blast Records, junto con el lanzamiento de la canción principal del álbum. As I Lay Dying es considerada una banda prominente de metalcore La banda también se conoce como metal cristiano, hardcore cristiano, thrash metal y death metal melódico. La música de I Lay Dying usa muchos elementos del death metal melódico. En una revisión de Beneath the Encasing of Ashes, Bradley Torreano de AllMusic describió el sonido de la banda como una mezcla de heavy metal, hardcore y grindcore.​ El escritor de heavy metal Garry Sharpe-Young describió a la banda como un "acto cristiano incondicional que emplea la voz de Grind del cantante Tim Lambesis y un toque distintivo de la guitarra escandinava"​ Como las influencias de I Lay Dying incluyen In Flames, Living Sacrifice, Iron Maiden, Slayer, At the Gates, Pantera, Megadeth, Fear Factory, Cannibal Corpse, Shai Hulud, Dark Tranquility, Metallica, Judas Priest y Earth Crisis. Entre sus influencias "no metal" Phil Sgrosso y Jordan Mancino destacan a Thin Lizzy, Pink Floyd y The Smashing Pumpkins​​​​​ En 2014, el antiguo líder de la banda Tim Lambesis declaró que aunque As I Lay Dying se dio a conocer como banda cristiana, en realidad él y otros miembros de la banda se volvieron ateos desde hace mucho tiempo. Dijo no haberlo admitido públicamente por temor a que bajaran las ventas de sus discos, y expresó que en su opinión, de todas las llamadas bandas cristianas de metal que ha conocido, solo una de cada diez es verdaderamente cristiana.

Georg Spöttle: Én ebben a háborúban maximálisan Oroszországot támogatom 444.hu     2022-11-02 14:39:59     Külföld háború Fidesz Moszkva HírTV Georg Spöttle A PestiSrácok és a Hír Tv visszatérő fideszes szakértője arról is beszélt, hogy már kért vízumot és engedélyt Moszkvától, hogy kimehessen forgatni az orosz frontra. Nyolcszoros gázszámlát kapnak a bérlakásban élők, Orbánhoz fordult két ellenzéki polgármester 24.hu     2022-11-02 12:26:43     Belföld Polgármester Rezsicsökkentés A szolgáltató szerint az önkormányzati tulajdonban levő lakóházakra nem vonatkozik a rezsicsökkentésről szóló kormányrendelet. Érdemes-e már bankbetétet választani állampapír helyett? G7     2022-11-02 15:39:17     Gazdaság Befektető Állampapír Tíz év után újra itt vannak a két számjegyű lekötött betétkamatok, de közben az állampapíroké is nőtt. Kié lesz végül a befektetők pénze? Magyarországról is beszélt az orosz védelmi miniszter 168.hu     2022-11-02 14:36:03     Külföld NATO Fehéroroszország A NATO kelet- és közép-európai erőinek létszáma két és félszeresére nőtt, jelenleg több mint 30 ezer katonát számlál, a közeljövőben pedig még növekedhet – jelentette ki Szergej Sojgu orosz védelmi miniszter szerdán az orosz és a fehérorosz katonai részlegével tartott közös tanácskozáson. 18 perc alatt fogyott el a kormányzati segély, felfüggesztették a regisztrációt Forbes     2022-11-02 10:36:02     Cégvilág Segély Elfogyhatott a 150 milliárd forint. 18 perc után felfüggesztették a kormány által meghirdetett Gyármentő Programba történő regisztrációt. A Nemzeti Befektetési Ügynökség (HIPA) honlapján annyi olvasható, hogy „a Gyármentő Programra történő regisztráció – a beérkezett regisztrációs űrlapok jelentős száma és forrásigénye miatt – felfüggesztésre kerül Öt lépéssel elérhető egy Kádár-kocka energetikai korszerűsítése, mutatjuk, mennyibe kerül Növekedés     2022-11-02 14:12:00     Gazdaság A vidéki utcakép meghatározó eleme a Kádár-kocka, a mai napig sok idős ember otthona, de szerényebb ára miatt a fiatal családok is szívesen választották az elmúlt években. Ám ha nincs szigetelve, akkor az idei tél rémálommá válhat, márpedig többségüknél az energetikai korszerűsítés még várat magára. Szakértő segítségével jártuk körbe, mi az az öt l Komoly bejelentés jött a magyar benzinkutakról: erre készülhetnek az autósok a héten Pénzcentrum     2022-11-02 13:35:00     Autó-motor Üzemanyag Tankolás Benzinár Eltérő irányba és eltérő mértékkel változnak pénteken az üzemanyagárak: a benzin ára bruttó 7 forinttal emelkedik, a gázolaj beszerzési ára viszont 20 forinttal csökken. Totális fordulat Moszkvában: fenyegetést látnak a magyarországi NATO-erősítésben is Privátbankár     2022-11-02 14:18:02     Külföld Románia Szlovákia Moszkva NATO Bulgária Bulgáriában, Magyarországon, Romániában és Szlovákiában új többnemzetiségű taktikai zászlóalj-csoportokat hoznak létre és ez veszélyes Oroszország számára - mondta Szergej Sojgu orosz védelmi miniszter. Már tömegével esnek el a frissen sorozott katonák Ukrajnában napi.hu     2022-11-02 15:09:00     Külföld Ukrajna Mozgósítás Az orosz kormány szeptember 21-én rendelte el a mozgósítást, és egy hónap alatt máris tucatszámra érkeznek a hírek azokról a frissen besorozottakról, akik életüket vesztették. Egy részük nem a harcok áldozata. Putyin kegyeit keresi a bajkeverő diktátor – Mit művel „Afrika Észak-Koreája” korunk egyik legvéresebb polgárháborújában? Portfolio     2022-11-02 13:00:00     Külföld háború Vlagyimir Putyin Afrika Remény csillant föl korunk egyik legvéresebb polgárháborúja, az etióp polgárháború lezárására, miután fegyverszüneti tárgyalásra ültek le Dél-Afrikában a kormányerők és Tigré tartomány lázadói. A tűzszünet és a béke legnagyobb gátja a szomszédos Eritrea lehet, amely az etióp kormányerők oldalán avatkozott be a háborúba, és történelmi sérelmeiért ak RTL25: „Retkes pizza a sok gyökérnek”, Stohl András fülébe durrantanak, a riporter röhögőgörcsöt kap egy motortól rtl.hu     2022-11-02 10:46:34     Bulvár Interjú Szilveszter Stohl András 10 éve ezek voltak az év legviccesebb pillanatai az RTL Híradó szilveszteri adásában. Volt, hogy a Híradó riportere egy percen át tette fel kérdését a türelmes interjúalanynak, mégsem belőle lett a 2012-es Híradók legendás mémszereplője, hanem a dühös pizzafutárból. 25 éves az RTL, ennek örömére sorozatunkban összegyűjtöttünk néhány emlékezetes fel Manuel Neuer először beszélt rákbetegségéről Rangadó     2022-11-02 13:33:00     Foci Rákbetegség Sajtóközleményben jelezte, hogy a bőrrák az arcán jelentkezett. Családtagjai megverésével vádolják a teniszelnököt 24.hu     2022-11-02 11:23:08     Sport Tenisz Miroslaw Skrzypczyskiról leleplező oknyomozó riport készült, szerinte az újságírók megpróbálnak beavatkozni a magánéletébe. Mediterrán ciklon hozhat jelentős esőt hétvégén Kiderül     2022-11-02 13:37:40     Időjárás Hétvége Hétvégén érkezik az időjárás-változás, mediterrán ciklon hozhat nagyobb esőt a jelenlegi adatok szerint főként hazánk nyugati felére.

Georg Spöttle: Én ebben a háborúban maximálisan Oroszországot támogatom 444.hu     2022-11-02 14:39:59     Külföld háború Fidesz Moszkva HírTV Georg Spöttle A PestiSrácok és a Hír Tv visszatérő fideszes szakértője arról is beszélt, hogy már kért vízumot és engedélyt Moszkvától, hogy kimehessen forgatni az orosz frontra. Nyolcszoros gázszámlát kapnak a bérlakásban élők, Orbánhoz fordult két ellenzéki polgármester 24.hu     2022-11-02 12:26:43     Belföld Polgármester Rezsicsökkentés A szolgáltató szerint az önkormányzati tulajdonban levő lakóházakra nem vonatkozik a rezsicsökkentésről szóló kormányrendelet. Érdemes-e már bankbetétet választani állampapír helyett? G7     2022-11-02 15:39:17     Gazdaság Befektető Állampapír Tíz év után újra itt vannak a két számjegyű lekötött betétkamatok, de közben az állampapíroké is nőtt. Kié lesz végül a befektetők pénze? Magyarországról is beszélt az orosz védelmi miniszter 168.hu     2022-11-02 14:36:03     Külföld NATO Fehéroroszország A NATO kelet- és közép-európai erőinek létszáma két és félszeresére nőtt, jelenleg több mint 30 ezer katonát számlál, a közeljövőben pedig még növekedhet – jelentette ki Szergej Sojgu orosz védelmi miniszter szerdán az orosz és a fehérorosz katonai részlegével tartott közös tanácskozáson. 18 perc alatt fogyott el a kormányzati segély, felfüggesztették a regisztrációt Forbes     2022-11-02 10:36:02     Cégvilág Segély Elfogyhatott a 150 milliárd forint. 18 perc után felfüggesztették a kormány által meghirdetett Gyármentő Programba történő regisztrációt. A Nemzeti Befektetési Ügynökség (HIPA) honlapján annyi olvasható, hogy „a Gyármentő Programra történő regisztráció – a beérkezett regisztrációs űrlapok jelentős száma és forrásigénye miatt – felfüggesztésre kerül Öt lépéssel elérhető egy Kádár-kocka energetikai korszerűsítése, mutatjuk, mennyibe kerül Növekedés     2022-11-02 14:12:00     Gazdaság A vidéki utcakép meghatározó eleme a Kádár-kocka, a mai napig sok idős ember otthona, de szerényebb ára miatt a fiatal családok is szívesen választották az elmúlt években. Ám ha nincs szigetelve, akkor az idei tél rémálommá válhat, márpedig többségüknél az energetikai korszerűsítés még várat magára. Szakértő segítségével jártuk körbe, mi az az öt l Komoly bejelentés jött a magyar benzinkutakról: erre készülhetnek az autósok a héten Pénzcentrum     2022-11-02 13:35:00     Autó-motor Üzemanyag Tankolás Benzinár Eltérő irányba és eltérő mértékkel változnak pénteken az üzemanyagárak: a benzin ára bruttó 7 forinttal emelkedik, a gázolaj beszerzési ára viszont 20 forinttal csökken. Totális fordulat Moszkvában: fenyegetést látnak a magyarországi NATO-erősítésben is Privátbankár     2022-11-02 14:18:02     Külföld Románia Szlovákia Moszkva NATO Bulgária Bulgáriában, Magyarországon, Romániában és Szlovákiában új többnemzetiségű taktikai zászlóalj-csoportokat hoznak létre és ez veszélyes Oroszország számára - mondta Szergej Sojgu orosz védelmi miniszter. Már tömegével esnek el a frissen sorozott katonák Ukrajnában napi.hu     2022-11-02 15:09:00     Külföld Ukrajna Mozgósítás Az orosz kormány szeptember 21-én rendelte el a mozgósítást, és egy hónap alatt máris tucatszámra érkeznek a hírek azokról a frissen besorozottakról, akik életüket vesztették. Egy részük nem a harcok áldozata. Putyin kegyeit keresi a bajkeverő diktátor – Mit művel „Afrika Észak-Koreája” korunk egyik legvéresebb polgárháborújában? Portfolio     2022-11-02 13:00:00     Külföld háború Vlagyimir Putyin Afrika Remény csillant föl korunk egyik legvéresebb polgárháborúja, az etióp polgárháború lezárására, miután fegyverszüneti tárgyalásra ültek le Dél-Afrikában a kormányerők és Tigré tartomány lázadói. A tűzszünet és a béke legnagyobb gátja a szomszédos Eritrea lehet, amely az etióp kormányerők oldalán avatkozott be a háborúba, és történelmi sérelmeiért ak RTL25: „Retkes pizza a sok gyökérnek”, Stohl András fülébe durrantanak, a riporter röhögőgörcsöt kap egy motortól rtl.hu     2022-11-02 10:46:34     Bulvár Interjú Szilveszter Stohl András 10 éve ezek voltak az év legviccesebb pillanatai az RTL Híradó szilveszteri adásában. Volt, hogy a Híradó riportere egy percen át tette fel kérdését a türelmes interjúalanynak, mégsem belőle lett a 2012-es Híradók legendás mémszereplője, hanem a dühös pizzafutárból. 25 éves az RTL, ennek örömére sorozatunkban összegyűjtöttünk néhány emlékezetes fel Manuel Neuer először beszélt rákbetegségéről Rangadó     2022-11-02 13:33:00     Foci Rákbetegség Sajtóközleményben jelezte, hogy a bőrrák az arcán jelentkezett. Családtagjai megverésével vádolják a teniszelnököt 24.hu     2022-11-02 11:23:08     Sport Tenisz Miroslaw Skrzypczyskiról leleplező oknyomozó riport készült, szerinte az újságírók megpróbálnak beavatkozni a magánéletébe. Mediterrán ciklon hozhat jelentős esőt hétvégén Kiderül     2022-11-02 13:37:40     Időjárás Hétvége Hétvégén érkezik az időjárás-változás, mediterrán ciklon hozhat nagyobb esőt a jelenlegi adatok szerint főként hazánk nyugati felére.

Fred Pescatore, MD is my guest. He is one of the most sought-after integrative physicians in the country. (Were it not for celebrities' need for privacy and HIPA, you would recognize the names of some of the high-profile patients of his Manhattan practice.) We will discuss recent research into what we should and should not be eating—e.g. the longstanding struggle over fats vs carbs. I also ask about intermittent fasting. Dr. Pescatore is the author of a number of books, including: The A-List Diet: Lose up to 15 Pounds and Look and Feel Younger in Just 2 Weeks; The Allergy and Asthma Cure: A Complete 8-Step Nutritional Program; and Feed Your Kids Well: How to Help Your Child Lose Weight and Get Healthy. On his website you will find a link to his newsletter and free report on Alzheimer's. Dr. Fred's YouTube channel shows cooking demos. This links to one of his recent shows on a trick to fool proof your diet. This links to his article on artificial sweeteners and cancer. We referenced this article on fake proteins. This is a book we discussed Cows Save the Planet: And Other Improbable Ways of Restoring Soil to Heal the Earth.  

This week on the Leadership Podcast,  Thomas Ntuk returns to join Bradley as they discuss key strategies for growing your insurance agency and any other business.  Thomas has numerous career highlights and accomplishments, and is sharing some of his tips with you today! They discussed the importance of investing in yourself.  Thomas shared that owners need to prioritize their own development first.  He also shared his new definition of “HIPA” aka High Income Producing Activities.  Finally, he emphasized the importance of never compromising in your career. Thomas joined Bradley on the podcast for two other episodes in March 2021 (Episodes 47 & 48: How To Improve Sales by Simplifying Parts 1 & 2). Thomas attended Thought Leaders' Summit in Hollywood, California.  During the summit, he was interviewed on the TV show Hollywood Live by the host, legendary Jack Canfield (Author of the Chicken Soup for the Soul series-which sold over 500 million copies). The show aired on both A&E and Bravo Networks. He also joined Brian Tracy, to co-author the Amazon Best Seller book, The Success Blueprint.  His agency accolades include Crystal Excellence, Ambassador Travel (29 years), Exotic Travel (6 years), Chairman's Circle (7 years), President's Club (7 years), Mutual Funds Leaders (all 7 years), Small Business Leaders (all five years). Learn more about Thomas Ntuk when you visit https://www.ntukspeaking.com/

ADÓZÁSRÓL ÉRTHETŐEN: SZJA, TAO, HIPA... Közeleg az éves bevallások határideje - Jancsa-Pék Judit, a LeitnerLeitner vezető tanácsadója, partnere ARANYKÖPÉS: Kóbor János ÉSZJÁTÉK: Euronics kötvénykibocsátás

Fred Pescatore, MD is my guest. He is one of the most sought-after integrative physicians in the country. (Were it not for celebrities need for privacy and HIPA, you would recognize the names of some of the high-profile patients of his Manhattan practice.) We will discuss his take on the recent research into what we should be and should not be eating. Dr. Pescatore is the author of a number of books, including: The A-List Diet: Lose up to 15 Pounds and Look and Feel Younger in Just 2 Weeks; The Allergy and Asthma Cure: A Complete 8-Step Nutritional Program; and Feed Your Kids Well: How to Help Your Child Lose Weight and Get Healthy. On his website you will find a link to his newsletter and free report on Alzheimer's. Dr. Fred's YouTube channel shows cooking demos. This links to a recent show on a trick to fool proof your diet. This links to his article on artificial sweeteners and cancer. We referenced this article on fake proteins. This is a book we discussed Cows Save the Planet: And Other Improbable Ways of Restoring Soil to Heal the Earth.  

Update on the Vail School District incident and being billed for mileage to deliver HIPA news to the parents of a student, which was left posted to the family's front door. Economist Stephen Moore joins Chris to talk about inflation and his study on how various states fared during COVID with their lockdown policies. For more information on Stephen, check out committeetounleashprosperity.com

This week Ruben violates his own HIPA laws and gives us a breakdown of his full medical history. T tries to steal Sisqo's place in Dru Hill. Then the crew goes over proper "Frank Stand"etiquette. Join us for another great episode of Who Gave y'all Mics.Follow Us At:Instagram: @whogaveyallmicsTwitter: @whogaveyallmicswebsite: wgympodcast.comFollow our host at:T:Instagram: @tstuddazTwitter: @tstuddazRuben:Instagram: @mr_youseeitCroslin:Instagram: @addicted2troubl3Six:Instagram: @justcallmesixDon't forget to tag #whogaveyallmics or @ us to let us know what you think of this week's episode!

Nick Hipa, Mire Shredbeast, formerly of As I Lay Dying, joins me on an all new episode of The Jasta Show! It's all PMA on this one as we get into the new album by Mire and what the plans for the future of the band is moving forward! Support Our SponsorsIndie Merch Store - https://www.indiemerchstore.com use promo code JASTA10 at check outMartyrstore - https://martyrstore.net use code JJ15The Mad Russian Apothecary - https://www.madrussianapothecary.com use code JASTA21Promescent - Use this link: https://bit.ly/3y9jZAP to get 15% off + free shipping automatically added on all orders!Seek and Strike - https://www.seekandstrike.com/Blue Chew - https://bluechew.com code JASTAFuckingGoodSoap.com use the code JASTA to save 10% on your order. Subscribe On GaS Digitalhttps://gasdigitalnetwork.com/gdn-show-channels/the-jasta-show/USE PROMO Code JASTA for a 2 week free trial.Follow Jamey On Patreonhttps://www.patreon.com/jastaFollow The Show On Social Mediahttps://twitter.com/jameyjastahttps://www.instagram.com/jameyjasta/https://twitter.com/bmackayisrighthttps://www.instagram.com/bmackayisright/Musician, former television host, and podcaster Jamey Jasta (Hatebreed, Kingdom of Sorrow, Jasta and the former host of MTV's Headbanger's Ball) interviews your heroes every Monday and Thursday. The newest 15 episodes are always free, but if you want access to all the archives, watch live, chat live, access to the forums, and get the show a week before it comes out everywhere else - you can subscribe now at gasdigitalnetwork.com and use the code JASTASee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today On The Jimmy Barrett Show:Will they threaten to take your health insurance away?Biden threatening to sick the U.S. Department of Education on states like Texas.Congressman Kevin Brady.The Heritage Foundations examination into vaccine efficacy.

Kiszámolós sorozatunk záró epizódja, melyből kiderül mennyibe kerül egy FOTÓ-VIDEÓ STÚDIÓ. Nyitnál egyet? Roland elmeséli az összes tapasztalatát a stúdió nyitásról, üzemeltetésről és fejlesztésről. A szokásos minimalista elvünket követve jöjjenek a kiadások: 50 KATA 200e-től Ingatlan 30-140 Rezsi 50-100e-től Új díszletek 5-10e Fogyó papír egyéb, tisztító szer, festés stb 4-5e Adobe 5e könyvelő 4e HIPA 1e Web 2e bank 40e marketing Szumma: 396e/506e havonta (nyári/téli kiadások) + eszközök karbantartása ,pótlása + x évente nagyobb felújítás (padló, hátterek, eszközpark) + esetleges alkalmazott... Az epizód tartalma: 00:00 Bevezető 00:01:36:15 Stúdió matek & Megfelelő ingatlan 00:09:58:14 Műterem specifikációi Külön díjazott smink szoba? Smink a fotózásra 00:25:24:10 BP-i ingatlan árak Rezsi Berendezés és fenntartás Berendezett műterem VS Technikai stúdió 00:33:10:22 Kreativitás VS ügyfél kérések Stúdióban 1 óra csak 45 perc? Fogyóeszközök 00:39:10:15 Plusz pénz a kellékekért? Háttér elhasználódás mítosz Gábor: Tűsarkú VS háttér További kiadások 00:47:02:11 Havi szumma Hány ember kell a rentábilis fenntartáshoz? Nyereség számolás Mikor lenne nyereséges? Vége van a résznek mert megjött a kaja :))) 00:54:12:23 Outro Nem csak hallgatnál minket hanem néznél is? Videókkal és extra tartalommal várunk a Youtube-on! https://bit.ly/3rdHk1d Zárt facebook csoportunk: https://www.facebook.com/groups/contentrumble Weboldal, insta, facebook, és más social media: https://contentrumble.hu E-mail elérhetőségünk: hello@contentrumble.hu TAGOK: CSAPÓ GÁBOR Facebook: https://www.facebook.com/csapogaborphotography Instagram: https://www.instagram.com/gabor_csapo_photography/ Átváltoztatjuk TEAM: https://www.facebook.com/AtvaltoztatjukTeam http://csapogabor.hu SZABÓ VIKTOR Youtube: https://www.youtube.com/c/szaboviktoryt?sub_confirmation=1 Instagram: https://www.instagram.com/szvinsta/ Facebook: https://www.facebook.com/szvhivatalos https://szaboviktor.com SZANYI ROLAND Instagram: https://www.instagram.com/studio69.hu/ Facebook: https://www.facebook.com/studio69.hu https://www.studio69.hu https://broadcasthub.hu --- Send in a voice message: https://podcasters.spotify.com/pod/show/contentrumble/message

In today's podcast we cover four crucial cyber and technology topics, including: 1. Issue with DDoS protection results in outages for Akami customers 2. Cosmolog Kozmetik data exposed in amazon cloud bucket 3. CVS exposes over 1 Billion health records in misconfigured database4. Texans claim energy companies raising thermostat settings remotely I'd love feedback, feel free to send your comments and feedback to  | cyberandtechwithmike@gmail.com

Morgós szerdán morgunk, aztán születésnapok, névnapok, évfordulók érkeznek a lapszemle és a tőzsdei helyzetkép előtt. BUDAPEST TE CSODÁS rovatunkban az eltűnő taxis hiénákról és a fővárosi személyfuvarozók helyzetéről szólunk. A pénzügyminiszter legyőzte Vasembert? - Janet Yelen kritikája összedöntötte a bitcoin árfolyamát. ÉBRESZTŐ rovatunk szakértője Szabó Dávid, a CryptoPosition Investment Fund portfóliókezelője. KKV ROVAT: Nyilatkozat kell az iparűzési adó felezéséhez - Mi történik, ha valaki nem tesz ilyet? E-BIZNISZ: Dél-Koreából érkezik az új Amazon? Palocsay Géza, a Jófogás és a Használtautó.hu ügyvezető igazgatója hívja fel a figyelmet az amerikai techóriások egyik lehetséges riválisára.

Születésnaposok, névnaposok, évfordulók után online lapszemle és tőzsdei helyzetkép. BUDAPEST TE CSODÁS: Miért hagyták lezülleni az ivócsarnokokat? - Molnár Zsuzska, a Járókelő.hu kommunikációs koordinátora. ÉBRESZTŐ TÉMA: Melyik lakossági állampapír a menő? - Árgyelán Ágnes, a portfolio.hu elemzője. KKV ROVAT: Automatikus csökkentés, határidő és felesleges adminisztráció HIPA-csökkentés ügyben. E-BIZNISZ: Autópiaci trendjelentés - Palocsay Géza, a Jófogás és a Használtautó.hu ügyvezető igazgatója.

Verbális tűzijátékkal köszöntjük a név- és születésnaposokat és emlékezünk a jeles eseményekre. Átfutjuk az újságok híreit és összefoglaljuk a tegnapi tőzsdenap eseményeit. Budapest, te csodás! rovatunkban a Bajza utcai halál alagútról és a fővárosban termelődő avar összegyűjtésének problematikájáról váltunk szót Molnár Zsuzskával, a Járókelő.hu sajtóreferensével. Magyarországon is elérhető a Google Pay! Szetnics László, a Mastercard regionális üzletfejlesztési vezetője mondja el a legfontosabb tudnivalókat erről.  KKV rovatunkban kicsit felhúzzuk magunkat a kamara elnökének újabb ötletén. Jó ötlet a helyi iparűzési adó (hipa) felfüggesztése? E-commerce rovatunkban Palocsay Géza, a Jófogás és a Használtautó.hu ügyvezető igazgatója elképesztő számokat mond arról, mekkora méretű is az Alibaba kínai online kereskedőcég. De ha ilyen sikeres, miért esik a tőzsdei árfolyama hetek óta?

Today, we break HIPA rules and, well, click-click-click. Inside joke. Gotta listen. And you gotta have a great weekend!

host @kbvisions2020

This podcast explores how readily available genomic testing and databases of human genetic information raise ethical concerns. Dr. McGuire discusses How information from direct-to-consumer genetic testing can be used and what to look out for, Where different lines of concern lie between genomic testing that prevents or treats disease and potential uses that are less clear, and What direction trends for the next few years are heading in the biomedical ethicist world while facing a pandemic. Dr. McGuire is the Leon Jaworski Professor of Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine. She specializes in ethical issues of genetic testing and genomic research.  Modern technologies and commercialization put human genetic information at the forefront of medical ethics revolving around multiple health issues. For example, she begins the conversation by addressing gene editing, which has brought a lot of attention: it offers great promise, but also raises ethical concerns about how we influence nature.  She also discusses privacy issues from direct-to-consumer genetic testing and genealogy information. She advises listeners to use caution and understand that who can access the information depends on the company you are using. She reviews different company policies but also the ways the fine print may include provisions the consumer can miss. Ultimately, these companies have created a business model to amass this data and sell it to pharmaceutical companies to develop health initiatives like new drugs. She talks about the extent to which HIPA and GINA, a newer suite of laws that directly address genomic research and human genetic testing information, meet the needs for protection yet could be tightened. She also brings up newer technologies and reproduction issues, some mass testing programs, and how balancing competing health issues with a global health emergency is a rising issue. For more, follow the work of the American Society for Bioethics and Humanities and see the web site for the Center for Medical Ethics and Health Policy at Baylor Medicine at https://www.bcm.edu/centers/medical-ethics-and-health-policy.

Annette takes a few minutes at the beginning to update listeners about social security during the COVID-19 crisis and what you can do to access your benefits as well as get answers from the social security office. As of the date of this podcast, the offices are closed due to the Coronavirus outbreak. Annette suggests setting up an account online with social security so you can access certain information. She offers tip for navigating the system during this time. Annette on this podcast talks about how to keep your planning updated for times of crisis and beyond. The Coronavirus crisis has caused many to take a step back and take a deeper look at their planning. Your plans always need to be buttoned up and, up to date but never more important than when the country and the world goes into a crisis. Annette runs through some of the most important items you need to be thinking of in your special needs planning. The first item she points out is to make sure you have a will and to make sure it is up to date. But it may not be the most important document in your plan. One of the more important items you should be looking at are incapacity documents. These are your healthcare proxy, power of attorney and your HIPA releases. But keep in mind, these documents are dictated by state laws and should be updated if you have moved. Annette goes through these documents in more detail in the podcast. The next item is guardianship and as Annette points out, this is different in every state as well. For example, standby guardians or backup plan can be different depending on the state so it is important to find out how state laws outline this. It is a good idea to speak with your attorney about guardianship for the best advice. Annette talks about having your trust planning in order. And specifically, special needs trusts. Laws may not have changed but the way public benefits can change over the course of time so it is important to revisit this document over time. Annette also discusses the Letter of Intent as another important document you should have. Everything from healthcare wishes, other wants and needs and specific directions should be in this letter. These are for anyone you have caregiving responsibilities for. They are wishes you have for your special needs loved one. Want to ask Annette a question? Find her at: https://specialneedscompanies.com/

Our next guest is Gianna Clayton, director of nursing for Atlantic Medicine and Wellness. With the recent outbreak of Coronavirus, doctors have had to adjust their ways of treating patients. Going to a hospital emergency room for symtoms, or any other illness is strongly discouraged, so "Telemed" is being implemented in order to be able to treat patients. There is an app called Anywhere Care.  This enables a person to have a video chat with their doctor.  The doctor can then assess the situation, and provide medicine , advice,  or reassurance to the patient. Another aspect of Telemed is addressing Mental Health Issues via a virtual visit with a therapist. These sessions are private and HIPA compliant.  The number for an appointment is 732-528-5533. 

You know how it be. We back at it again. Holla at yo boy and tell them to gather around and listen to this week's episode. Amina, Samrah, and Zain talk about lingering feelings for GOT, breaking rules for that money, rants about Aladdin, and much more!       Subscribe on iTunes, Podbean, Google Play, Spotify, Stitcher, or wherever you get your podcasts!  Like us on FB: https://www.facebook.com/fobandfriends Follow us on Twitter and Instagram: @fobandfriends https://fobandfriends.com

A helyi iparűzési adó, az adónem létezése óta magában hordozza a ráfordítások helyes kategorizálásának kockázatát. Egy friss Kúriai ítélet pedig még tovább bonyolíthatja az eddig sem mindig egyértelmű helyzetet. Milyen szereplőket érinthet a Kúria döntése? Mi minősül készterméknek és mi igénybevett szolgáltatásnak a HIPA szempontjából? A témáról Farkas Gábor kérdezte Burján Ákost, a PwC Magyarország cégtársát.

La fotografia è un'autentica bugia? Parliamo di questo tema commentando la fotografia vincitrice del premio HIPA 2018-19 da 120.000 dollari. La fotografia in questione ha spaccato in due il web per via del backstage emerso che mostra come lo scatto vincitore è stato realizzato. E' etico oppure no? Delude perchè costruito e non naturale? Scoprilo insieme a noi!

Welcome to a metalcore episode of Zealous Musician. Let's dive into all things As I Lay Dying: crazy guitar licks, wicked fast drums, brutal screaming, and an unbelievably tragic story... redeemed.   - - - - - - - - - - -   Spotify Playlist https://open.spotify.com/user/marcorandazzo/playlist/5sAntXC8vhcJ7z30c3YRs3?si=Q5p7X5EGSnOkADnjjZ9SmA Special thanks to my guest Jordan Hunsucker   Unstoppable Recording Machine Podcast: interview with Phil Sgrosso https://urm.academy/ep158-phil-sgrosso/   Metal Sucks Podcast: Interview with Jordan Mancino http://www.metalsucks.net/2016/10/17/jordan-mancino-of-wovenwar-on-the-metalsucks-podcast-167/   Connect with Zealous Musician Twitter @zealousmusician Instagram @zealousmusician Contact me marco@zealousmusician.com Subscribe to the email list www.zealousmusician.com     Super Team Media

ABOUT THIS EPISODE Eli Paley grew up with rich family history - the son of a survivor and a long-standing scion of Jerusalem aristocracy. Early love of Torah story fused with business interests, and Eli found himself at the helm of the fledgling Mishpacha Magazine, which he ultimately  catalyzed into a media empire. In more recent years, he founded the Haredi Institute for Public Affairs, a multi-disciplinary think tank aimed at offering research-driven solutions to this population's most vexing challenges. In that role, he is helping change the conversation - and the perception - surrounding a prominent and growing demographic, and with it, Israeli society at large. -------------------- ABOUT THIS PODCAST Jews You Should Know introduces the broader community to interesting and inspiring Jewish men and women making a difference in our world. Some are already famous, some not yet so. But each is a Jew You Should Know. The host, Rabbi Ari Koretzky, is Executive Director of MEOR Maryland (www.meormd.org), a premier Jewish outreach and educational organization. MEOR operates nationally on twenty campuses and in Manhattan; visit the national website at www.meor.org. Please visit www.JewsYouShouldKnow.com, follow us on Twitter @JewsUShouldKnow or on Facebook. Have feedback for the show, or suggestions for future guests? E-mail us at JewsYouShouldKnow@gmail.com. Want to support this podcast? Visit Patreon.com/JewsYouShouldKnow. A small monthly contribution goes a long way!! A special thank you to Jacob Rupp of the Lift Your Legacy podcast for his invaluable production assistance.

This week we finish up our discussion of useful vocabulary related to health care, including talk about networks, pre-existing conditions, HIPA, Obamacare vs. the ACA, and primary care physicians. Subscribe on iTunes Download mp3 On Stitcher Cartoon accompaniment: Links: About “Yankee Doodle” in The New York Times. This week's calendar entry is “sick/sic.” Buy the … Continue reading Episode 104: Finishing Up Health Care Terms: Networks, HMOs, Pre-existing Conditions, HIPA, and Primary Care Physicians

VJ aka the Brown James Bond + Toly aka T $ Malone chop it up some more. Bill Burr + Nia Burr. Nia Long is fine. Toly fake spits in VJ's drink. VJ has been getting denied lately. New apartments by ASU. VJ's spot is sorta nice? Is the AC good or bad? "Do you breathe scumbag?" T $ is a super producer. F-Dawg's birthday is coming up. "I'm not a fan of white people my n*gga!" Toly's intro is dope. Cam'ron throwing Jay-Z off a song. Jay-Z latest verses been sorta ehh. GURU the producer. Federico Fellini. Chris Brown is artistic. Is Rihanna worth falling for? Lady Gaga vs Beyonce. What do you need to buy a gun? Lowkey Lonely only backs Trump because Rubio is trash. Shady Lyft tactics. Toly's homie hit him with a Venmo scam. Motivation for life is to be great. Being the son of a scumbag. Klip gets in a car accident and VJ + Toly rush over while talking HIPA. A lot of things have changed since 2007. Klip is probably about to get a DUI charge. Does the homie have a straight drug problem? PLEASE FOLLOW US AND SUBSCRIBE!!! Pshow and art produced by VJ aka the Brown James Bond: instagram.com/ItsMrVJ twitter.com/ItsMrVJ facebook.com/ItsMrVJ SnapChat: ItsMrVJ The Psycho Pshow: instagram.com/PsychoPshow twitter.com/PsychoPshow facebook.com/psychopshow Please SUBSCRIBE & REVIEW on iTunes, Stitcher and YouTube! Thank you, love you and stay up!!!

My conversation backstage at "Ozzfest meets Knotfest" with Wovenwar guitarist Nick Hipa. We talk about playing at Glen Helen, playing on stage with Slipknot. We also dig into the 2nd Wovenwar album "Honor Is Dead" (out now). We talk San Diego, Chargers, Craft Beer, his venue "Brick By Brick" and more

In this FREE 30-minute Practice Management Nugget Webinar with Dustin Rivers you will get a behind-the-scenes peak at the upcoming 2016 Saskatchewan Connections conference. http://informationmanagers.ca/Connections The Connections events are each regionally based conferences designed for Access, Privacy, Security and Information / Records Management professionals working for public agencies. Through a series of plenary, breakout and workshop sessions, delegates will gain a clearer understanding of access to information, protection of privacy, information security, and records management issues that arise in organizations subject to FOIP, LAFOIP, and HIPA. More importantly, discussion focuses on the connections between these disciplines. 25+ sessions and 35+ speakers over 2 daysRegina SK May 10-11, 2016 Learn how you can 7x your professional education starting with listening to this interview with Dustin Rivers, Executive Director, Verney Conference Management right now! Register for 2016 Saskatchewan Connections #SK_Connections @SK_Connections http://skconnections.ca Brought to you by your Practical Privacy Coach and Practice Management Mentor http://www.informationmanagers.ca

Nick Hipa is one of those rare humans who just makes you feel really good when you talk to him– one of those guys who makes you feel like the […] The post Music & Audio podcast 33: Nick Hipa of Wovenwar appeared first on CreativeLive Blog.

Interview aired the weekend of 8/15-8/18 on rock stations around the U.S. Go to fullmetaljackieradio.com for more info.

This week, guitarist Nick Hipa goes on the record about Tim Lambesis, the demise of As I Lay Dying, and the rise of Wovenwar, his new band with the other former members of AILD. The chat went so long, this episode is pretty much dedicated solely to the interview!

Hipa ja Nuppu nauttivat talvihangesta. Mitähän jännittävää heidän talvipäiväänsä kuuluu? Eeva-Leena Malander on kirjoittanut ja kertoo sadun. KOHDERYHMÄ: 3-8-vuotiaat. Joulutarina vuodelta 2011. Osa 6 sarjasta Tarinakuusi.

Hipa ja Nuppu nauttivat talvihangesta. Mitähän jännittävää heidän talvipäiväänsä kuuluu? Eeva-Leena Malander on kirjoittanut ja kertoo sadun. KOHDERYHMÄ: 3-8-vuotiaat. Joulutarina vuodelta 2011. Osa 6 sarjasta Tarinakuusi.